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Re sume  
 
Il a été montré récemment que l’interaction physiologique entre le co-répresseur nucléaire 
SMRT et le facteur de transcription cellulaire STAT3 pouvait être perturbée par la protéine 
EBNA2 du virus Epstein-Barr (EBV). Normalement, SMRT réduit l’activité transcriptionnelle 
de STAT3. La dissociation de SMRT médiée par EBNA2 est donc supposée augmenter la 
transcription des gènes de l’hôte et viraux régulés par STAT3. STAT3 régule plusieurs effets 
immunosuppresseur, mais aussi pro-prolifératif et anti-apoptotique. Cette activité pourrait 
donc être importante pour la stratégie de survie du virus. EBNA2 et SMRT sont prédites 
comme étant des protéines intrinsèquement désordonnées (IDPs), comme environ un tiers 
des protéines eucaryotes. Malgré cette abondance, notre compréhension de la relation 
structure-fonction des IDPs est limitée, partiellement parce qu’il est difficile de produire des 
échantillons stables et en grande quantité, ce qui est nécessaire pour des études 
structurales et biophysiques. La technologie de bibliothèque aléatoire ESPRIT a été utilisée 
pour résoudre ce problème et générer des fragments solubles et s’exprimant bien d’EBNA2 
et de SMRT, d’une taille adaptée à des études biochimiques, biophysiques et RMN, pour 
étudier leurs interactions avec STAT3. Les régions d’interaction ont été cartographiées avec 
une résolution à l’acide aminé près, et ont été confirmées par mutagenèse. Les affinités ont 
été déterminées par différentes méthodes, démontrant qu’EBNA2 se lie à STAT3 avec une 
affinité de l’ordre du nanomolaire, et approximativement dix fois plus fort que SMRT. Des 
expériences utilisant la luciferase comme rapporteur ont été effectuées pour tester les 
interactions de mutants d’EBNA2 en cellules de mammifères en observant l’expression des 
gènes contrôlés par STAT3. Ces données suggèrent qu’un simple mécanisme de 
compétition pourrait expliquer comment EBNA2 active STAT3 lorsqu’il est réprimé, et ouvre 
de nouveaux horizons pour des études fonctionnelles cherchant à comprendre comment 
EBV établit et maintient la latence dans la cellule hôte. 
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Abstract 
 
It was recently shown that the physiological interaction between the nuclear corepressor 
SMRT and the cellular transcription factor STAT3 could be disrupted by the Epstein-Barr 
virus (EBV) protein EBNA2. SMRT normally decreases the transcriptional activity of STAT3, 
thus EBNA2-mediated release of SMRT is expected to enhance the transcription of host and 
viral STAT3 regulated genes. STAT3 regulates several immunosuppressive as well as pro-
proliferative and anti-apoptotic effects in the host organism and so this activity may be 
important for the viral survival strategy. Bioinformatics predict both EBNA2 and SMRT to be 
intrinsically disordered proteins (IDPs), in common with about one third of all eukaryotic 
proteins. Despite this abundance, our understanding of how this property relates to function 
is limited, in part due to difficulties in production of stable samples in the large quantities 
necessary for structural and biophysical studies. The ESPRIT random library technology was 
used to overcome these problems and generate soluble well-expressing fragments of 
EBNA2 and SMRT that were of suitable size for biochemical, biophysical and NMR 
experiments to study their interactions with STAT3. The interaction regions were mapped to 
individual amino acid resolution and confirmed by mutagenesis. Affinities were determined 
by different methods demonstrating that EBNA2 binds STAT3 with nanomolar affinity, and 
approximately ten-fold more tightly than SMRT. Luciferase reporter assays were performed 
in order to test mutants of EBNA2 binding in mammalian cells, and effects on STAT3 
mediated reporter gene expression were observed. These data suggest that a simple 
competitive mechanism may explain how EBNA2 activates repressed STAT3, and open the 
way for future functional investigations into how EBV establishes and maintains latency in 
the host cell. 
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Introduction 
Résumé 
L’introduction présente premièrement la biologie des virus herpès en général. Les virus 
herpès sont des virus enveloppés dont l’ADN double brin est encapsidé dans une capside 
icosaédrique. Ils peuvent être divisés en trois sous-familles : alpha-, beta- et 
gammaherpesviridae. Le virus Epstein-Barr (EBV) est un des huit virus herpès pathogènes 
et appartient au groupe des herpès virus gamma et au genre lymphocryptovirus. C’est aussi 
le premier virus a avoir été associé au cancer humain. En plus de son association avec le 
cancer, l’infection lytique par EBV peut causer la mononucléose infectieuse (IM). D’après 
l’OMS, plus de 95 % de la population mondiale est séropositive pour EBV, mais à ce jour 
aucun traitement efficace contre EBV n’existe sur le marché. Une caractéristique spécifique 
d’EBV est que le virus persiste toute la vie dans l’organisme hôte et peut être réactivé à 
n’importe quel moment en cas de conditions immunosuppressives chez l’hôte. Pendant les 
phases de latence, le virus est silencieux et seulement quelques gènes viraux sont exprimés. 
Une des protéines exprimée pendant la latence III est l’antigène nucléaire 2 d’EBV (EBNA2). 
EBNA2 est un activateur transcriptionnel, la première protéine exprimée pendant l’infection 
des cellules B. Elle joue également un rôle important dans l’activation de cellules B au repos 
et stimule leur prolifération en régulant positivement l’expression de gènes viraux et en 
régulant négativement l’expression de gènes cellulaires. Il a été montré récemment que, lors 
de l’infection, EBNA2 interagit avec le facteur de transcription cellulaire STAT3. Cette 
interaction pourrait augmenter la transcription des gènes de l’hôte et du virus régulés par 
STAT3. La signalisation activée par STAT3 est pro-prolifération, anti-apoptotique, et a 
plusieurs effets de suppression immune. De plus, il a été proposé que STAT3 soit requise 
pour maintenir l’état latent. Une augmentation du niveau de STAT3 est de ce fait importante 
pour la stratégie de survie du virus EBV. En conditions physiologiques, STAT3 est liée à la 
protéine co-répresseur médiatrice pour les récepteurs aux hormones rétinoïdes et thyroïdes 
(SMRT). Cette interaction réduit l’activité transcriptionnelle de STAT3. EBNA2 et SMRT sont 
des protéines intrinsèquement désordonnées (IDPs), comme environ un tiers des protéines 
eucaryotes et 70 % des protéines liées au cancer. Des études structurales détaillées 
d’EBNA2 et SMRT n’existent pas. Cependant, d’après certains systèmes mieux compris, 
l’importance des IDPs dans diverses pathologies, y compris dans le cancer et les maladies 
neurodégénératives, est claire. Les IDPs sont fortement liées au cancer du fait de leur rôle 
actif dans la prolifération, l’apoptose, le contrôle du cycle cellulaires et l’angiogenèse. EBNA2 
et SMRT sont des exemples de la façon dont les IDPs entrent en compétition pour influencer 
la transcription contrôlée par STAT3.  
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1.1 Herpesviridae 
Herpesviridae can be divided into three subfamilies: alpha-, beta- and gammaherpesviridae. 
A typical herpesvirion contains a double-stranded DNA genome which is packed into the 
core, an icosadeltahedral capsid made up of 162 capsomeres, a tegument that surrounds 
the capsid and an envelope with viral glycoprotein spikes on the surface. The genome is 
120-230 kbp and linear, but circularises immediately upon release from the capsid into the 
nucleus of the host cell. It comprises unique regions that are disrupted by internal and 
terminal repeated regions. Latency is a special feature of all herpesviruses whereby the virus 
stays quiet in the host cells and only a few viral gene products are expressed. Under 
immunosuppressive conditions the virus can be reactivated and enters the lytic replication 
cycle that is characterised by the irreversible destruction of the infected cell and the 
production of progeny viruses (Fields et al., 1996). 
1.1.1. Epstein-Barr virus 
Epstein-Barr virus (EBV) was discovered in 1964 when Anthony Epstein and Yvonne Barr 
isolated the virus from Burkitt’s lymphoma biopsy samples and identified it by electron 
microscopy (Epstein et al., 1965). EBV was also the first virus to be associated with human 
cancer. It is one of eight human pathogenic herpesviruses and belongs to the group of 
gammaherpesviruses and the lymphocrytovius genera. Different subtypes are described in 
the literature at which the strains P3HR-1 and B95-8 are the most studied (Bornkamm et al., 
1980). The EBV genome has a size of 172 kbp and contains two direct repeats at the ends 
and an internal repeat that divides the genome into short and long unique regions (Fields et 
al., 1996).       
1.1.1.1. Replication cycle 
The virus binds to cells via its glycoproteins gp 220 and gp350 (Nemerow et al., 1987) to the 
CD21 integral membrane receptor. It is then internalised into cytoplasmic vesicles and fusion 
of viral and cellular membrane leads to the release of the nucleocapsid into the cytoplasm 
which is transported along the microtubules to the nuclear pores. The genome is released 
from the nucleocapsid and enters the nucleus where it circularises. Two distinct replication 
cycles can be distinguished: the lytic and the latent replication cycle. During the lytic phase 
all viral proteins are expressed whilst in latency there is expression of only a few proteins 
and RNAs. One of these is EBNA2 which is also referred as the transforming antigen of the 
virus. Viral transcription occurs in three phases: immediate early, delayed early and late 
transcription. After replication of the genome, which occurs via a rolling cycle mechanism, the 
progeny viral particles bud away from the nuclear membrane (transport budding) and then 
from the endoplasmic membrane (maturation budding). The viral particles are released from 
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the host cell following fusion with the cell membrane (Mettenleiter et al., 2009). The 
replication cycle of EBV is summarised in Fig. 1.1. 
 
 
 
Figure 1.1: Epstein-Barr viral replication cycle. (A) The enveloped virus binds host cell surface 
receptors. (B) After fusion of viral and cellular membrane the capsid is released into the cytoplasm and 
(C) transported to the nucleus. (D) The virus docks to the nuclear pore (NP) where the viral genome is 
released into the nucleus and circularizes. (E) Viral genes are transcribed and the viral genome 
replicates. (F)Viral DNA is packed into preformed capsids and (G) leaves the nucleus (transportation 
budding). (H) Final maturation occurs in the cytoplasm by budding of the viral capsid into vesicles of 
the trans-golgi network which contain viral glycoproteins. (I) The enveloped virion is transported to the 
cell surface and is released into the outer cellular space by fusion. Picture modified from (Mettenleiter, 
2004) and used with permission from the author. 
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1.1.1.2.  Infectious mononucleosis and cancer due to EBV 
According to the WHO over 95% of the world’s population is seropositive for EBV (WHO | 
Viral Cancers). In most of the cases primary infection occurs during early childhood and is 
asymptomatic. In adults lytic infection can cause infectious mononucleosis which is marked 
by atypical lymphocytosis (Michelow et al., 2012). Classical symptoms are the triad of fever, 
oropharyngitis, and a bilateral and symmetrical lymphadenitis in the posterior triangle of the 
neck (Lawee, 2007). Furthermore, the virus has been associated with 1% of globally 
occurring cancer cases (Parkin, 2006). It is implicated in the causation of cancers like 
Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma, primary central 
nervous system lymphoma (PCNSL) and posttransplant lymphoproliferative disease (PTLD) 
(Young and Rickinson, 2004). 
1.1.1.3. Therapy 
Acyclic nucleoside and nucleotide inhibitors, which are used as antiviral drugs, have a high 
specificity as they require phosphorylation to their triphosphorylated forms in order to be 
active and they are favoured by the viral kinase (Clercq and Holy, 2005; Jordheim et al., 
2013). Therefore they are able to inhibit the viral polymerase but are inactive in uninfected 
cells. Unfortunately, they are only effective in cell culture and their use for the treatment of 
acute infectious mononucleosis in humans is quite limited (Young and Rickinson, 2004). 
Reasons for this are the long incubation time of 4-6 weeks, the location of EBV in the saliva 
which is difficult to access by orally administrated drugs, and the fact that most symptoms of 
IM are not due to cytopathic effects of the virus but rather due to immunopathic responses to 
EBV-infected cells.  
1.1.1.4. Latency 
A special feature of EBV is that the virus persists lifelong in the host organism and can be 
reactivated at any time under immunosuppressive conditions. During latency the virus 
remains silent in the cell with only a few viral genes being expressed (Young and Rickinson, 
2004). Three latent membrane proteins (LMPs 1, 2A and 2B) and six EBV nuclear antigens 
(EBNAs 1, 2, 3A, 3B, 3C and -LP) can be detected, as well as two viral RNAs (EBER1 and 
EBER2). All EBV associated cancer malignancies are characterised by latent gene 
expression. Four latency types are characterised by different gene expression profiles and 
are associated with different cancers as indicated in Table 1.1 (Kuppers, 2003). 
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 Expressed genes 
Associated 
disease(s) 
Latency 0 EBERs, LMP2A - 
Latency I EBERs, EBNA-1 
Burkitt lymphoma, 
Primary effusion 
lymphoma (PEL) 
Latency II EBERs, EBNA-1, LMP1, LMP2A Hodgkin lymphoma 
Latency III 
EBERs, EBNA-1, EBNA-2 LMP1, 
LMP2A, EBNA3s, EBNA-LP 
Post-transplant 
lymphoproliferative 
disease (PTLD) 
 
Table 1.1.: Different protein expression during latency 0-III is associated with different malignancies 
(Kuppers, 2003). 
 
1.1.1.5. EBV nuclear antigen 2 (EBNA2) 
The latent protein EBV nuclear antigen 2 (EBNA2) is a transcriptional activator, the first 
expressed protein during B-cell infection, and is essential for B-cell growth transformation 
(Young and Rickinson, 2004). It plays an important role in the activation of resting B-cells 
and stimulates their proliferation by upregulating the expression of viral genes, and by up- 
and downregulating cellular genes. EBNA2 does not regulate transcription by direct binding 
to DNA but by interacting with host proteins including transcription factors. EBNA2 is a highly 
promiscuous protein and undergoes interactions with many binding partners as confirmed by 
yeast two-hybrid screening of the EBV-EBV and EBV-human interactome (Calderwood et al., 
2007). One EBNA2 interaction partner is the signal transducer and activator of transcription 3 
(STAT3) (Muromoto et al., 2009a). In transcription assays, EBNA2 interacts with the 
transcription factor STAT3 and enhances its activity. STAT3 has been shown to be 
differentially expressed during infection by several different herpesviruses (King, 2013; 
Reitsma et al., 2013; Chung et al., 2004), and recently it was shown to enhance proliferation 
in B-cells from patient samples (Koganti et al., 2013). Generally then, it is involved in the 
immune response modulation of the host organism. The transcriptional activation by EBNA2 
via a well characterized interaction with the transcription factor CBF1 (also called RBP-J) 
has been described (Henkel et al., 1994; Ling and Hayward, 1995) (Fig. 1.2). EBNA2 also 
activates transcription via CBF1 independent pathways (Grabusic et al., 2006). 
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Figure 1.2: CBF1-mediated transcriptional activation by EBNA2 (A) The multi-protein complex 
containing SIN3A, HDAC1/2, SAP30, CIR, SKIP, SMRT and CBF1 represses transcription when 
bound to DNA. (B) EBNA2 competes with the HDAC-SMRT co-repressor complex for binding to CBF1 
and recruits the basal transcription machinery to activate transcription. (Young and Rickinson, 2004). 
 
EBNA2 is 487 amino acids long and bioinformatically predicted to be largely intrinsically 
disordered using tools such as IUPRED (Dosztányi et al., 2010). Despite the lack of three-
dimensional domain structures there are still functional domains in EBNA2 which can be 
distinguished (Fig. 1.3) (Zimber-Strobl and Strobl, 2001). The N terminus contains a 
homodimerisation domain which is followed by a long poly-proline stretch (10-40 aa). The 
diversity region is located in the middle of the protein where the homology between the two 
known variants (EBNA2A and EBNA2B) is very low. The RBP-J (CBF1) binding region and 
an arginine-glycine stretch follow. The C terminus contains the negatively charged 
transactivation domain and the nuclear localisation signal.  
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Figure 1.3: EBNA2 functional domains. Adapted from (Zimber-Strobl and Strobl, 2001). DIM = 
dimerisation domain, Pro = Proline stretch, RBP-J binding region, ArgGly = arginine glycine rich 
region, TAD = transactivation domain, NLS = nuclear localisation signal. 
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1.2. Signal transducer and activator of transcription 3 
(STAT3) 
 
STAT3 is a transcription factor that is activated due to growth factor and cytokine stimuli. The 
first identified cytokine that activates STAT3 signaling is IL-6 (Zhong et al., 1994). Binding of 
this cytokine and other growth factors to cell surface receptors leads to auto-phosphorylation 
of the cytoplasmic part of the receptors. Monomeric STAT3 is recruited to the phosphorylated 
receptor and gets phosphorylated either directly by the receptor or by associated Janus-
kinases. Tyrosine-phosphorylation of the STAT3-SH2 domain causes dimerisation of STAT3 
and its translocation to the nucleus where it binds to the promoter region of its target genes 
(Fig. 1.4). STATs use different importins for nuclear trafficking with STAT3 binding both 
importin-3 (Liu et al., 2005) and(Cimica et al., 2011). Shuttling in and out of the nucleus 
is presumably tyrosine phosphorylation independent (Liu et al., 2005). Besides this classical 
role in the nucleus, STAT3 was shown to stimulate oxidative phosphorylation in mitochondria 
and to support Ras-dependent oncogenic transformation (Gough et al., 2009). Another 
function of unphosphorylated STAT3 is to bind NFB and facilitate its import to the nucleus 
(Yang and Stark, 2008).  
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Figure 1.4: The JAK/STAT3 signaling pathway (Yu et al., 2007). IL-6 or LIF bind to the cell surface 
receptor leading to an auto-phosphorylation of the cytoplasmic receptor domain. STAT3 monomers 
are recruited to the phosphorylation site and are tyrosine-phosphorylated either directly by the 
receptor or by associated Janus-kinases. Phosphorylation of the STAT3-SH2 domain causes its 
dimerisation and translocation into the nucleus where it binds to the promoter region of its target 
genes 
 
STAT3 was discovered in 1994 by two independent groups (Zhong et al., 1994; Akira et al., 
1994). It is one of 7 STAT family members alongside STATs 1, 2, 4, 5a, 5b, and 6. Early 
functional studies (prior to the availability of structures) had defined four functional STAT3 
domains: the 130 aa N-terminal domain was shown to mediate co-operative sequence 
specific DNA binding of multiple DNA sites (Vinkemeier et al., 1996; Xu et al., 1996). Amino 
acids 400-500 engage in DNA binding specificity but do not facilitate DNA binding alone 
(Horvath et al., 1995). The SH2 domain is located between amino acids 600-710 and 
mediates the dimerisation of two monomers after phosphorylation of tyrosine 705 (Shuai et 
al., 1994). The C terminus is associated with transcriptional activation and can be modulated 
by phosphorylation of serine 727 (Wen et al., 1995). 
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In 1998, the structure was solved of the murine STAT3 homodimer bound to DNA which 
shares over 99% sequence similarity with human STAT3 (Becker et al., 1998b). In the same 
year the structure of the N-terminal domain of STAT4, which shares a sequence similarity of 
about 50% with the human STAT3, was released (Vinkemeier et al., 1998a). However, 
solving the structure of a STAT3 monomer turned out to be a more challenging task. The 
murine structure was solved only in 2008 (Ren et al., 2008). Fig. 1.5 shows the crystal 
structures of the N-terminal domain of STAT4 (aa 1-123) and of the STAT3 homodimer (aa 
127-722) bound to DNA. The crystal structure of STAT3 shows that it is comprised of a N-
terminal 4-helix bundle (in purple) followed by -barrels (in red), a connector domain (in 
green) and the SH2 domain (in yellow) (Becker et al., 1998b).   
 
 
Figure 1.5: Structures of N-terminal STAT4 (1-123) and C-terminal STAT3 (127-722). The STAT4 
structure contains aa 1-123 (Vinkemeier et al., 1998b) and the STAT3 structure is obtained from the 
truncated -isoform which is comprised of aa 127-722 (Becker et al., 1998b). 
 
1.2.1. Functions of STAT3 and possible advantages for the 
virus in “hijacking” STAT3 
 
It is not known for certain why EBV manipulates STAT3 signaling, however there are many 
clues in the litreature relating to the role of STAT3 in cell cycle control and 
immunosuppression. These functions indicate that hijacking STAT3 may be to the advantage 
of the viral survival strategy. A notable recent publication hypothesised that STAT3 signaling 
might be responsible for cell proliferation and survival in EBV infected B cells (Koganti et al., 
2013). Another hypothesis claiming that STAT3 is required for maintance of the latent state 
upon HSV infection may also be significant (Du et al., 2013). 
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1.2.1.1. STAT3 in cell cycle control 
The elucidation of STAT3 functions is not simple as deletion of STAT3 leads to embryonic 
lethality with rapid embryonic degeneration between day 6.5 and 7.5 (Takeda et al., 1997). 
However, extensive studies of the STAT3 signaling pathway revealed the involvement in 
proliferation, apoptosis, angiogenesis and immune control. STAT3 signaling enhances 
proliferation through upregulation of the expression of Bcl-2, Bcl-XL (Zushi et al., 1998), Mcl-1 
(myeloid cell leukaemia-1), cyclin-D1 and c-Myc (Bromberg et al., 1999; Rahaman et al., 
2002). On the other hand STAT3 was shown to inhibit apoptosis (Shen et al., 2001; Zushi et 
al., 1998; Aoki et al., 2003; Bhattacharya et al., 2005) and promote angiogenesis (e.g. 
VEGF) (Aggarwal et al., 2006). Besides the canonical pathway and gene expression 
regulation STAT3 functions though interaction with other transcription factors like PPAR-
(Wang et al., 2004-catenin (Hao et al., 2006), NFB (Yu et al., 2002; Jang et al., 2004), 
HIF1 (Jung et al., 2005), Pim-1 and c-myc (Shirogane et al., 1999), c-fos (Yang et al., 
2003), c-jun (Yoo et al., 2001), glucocorticoid receptors (Zhang et al., 1997) and estrogen 
receptors (Wang et al., 2001). 
1.2.1.2. STAT3 in immunosuppression 
STAT3 mediates immunosuppression at many levels. On one hand it retrains the immune 
response by antagonising NFB and STAT1 mediated expression of T helper 1 (TH1) 
cytokines such as IL-12 (Kortylewski et al., 2009) and interferon- (INF) (Kortylewski et al., 
2005a) which are both necessary for innate and adaptive immune response, and on the 
other hand, STAT3 is essential for anti-inflammatory reactions mediated by IL-6 (Berg et al., 
1996). The restriction of the adaptive immune response is mainly mediated by regulatory 
TH17 cells. STAT3 is essentially involved in the development of TH17 cells which requires IL-
6 and TGF and is further promoted by IL-12 and IL-23 (Gerosa et al., 2008). STAT3 
functions as the major IL-6R-dependent transcription factor in the T cell and as a 
transcription activator of IL-23a (Kortylewski et al., 2009). 
1.2.2. STAT3 in malignancies 
Up-regulation of STAT3 signaling is implicated in a wide range of human cancers including 
e.g. breast cancer, multiple myeloma, head and neck cancer, leukemia, lymphoma and lung 
cancer (Bowman et al., 2000). Furthermore STAT3 was shown to be persistently tyrosine 
705 phosphorylated in nasopharyngeal carcinoma (NPC) (Lui et al., 2009; Ho et al., 2013) 
and also in Hodgkin’s lymphoma cells STAT3 was found to be constitutively active (Chen et 
al., 2001) which establishes the connection between EBV associated cancer and STAT3. 
Dominant negative mutations in the STAT3 DNA binding domain could be identified as the 
cause of hyper IgE syndrome (Minegishi et al., 2007; Casanova et al., 2012). 
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1.2.3. STAT3 inhibitors 
Aberrant activation of STAT3 signaling is a common feature of many cancer types and has 
established STAT3 as a target for the pharmaceutical industry. Many efforts have been 
made to develop novel anticancer drugs targeting STAT3 signaling including: i) direct 
targeting of STAT3 on the protein level; ii) targeting of STAT3 on the DNA/RNA level; iii) 
targeting of STAT3 signaling upstream molecules; iv) inhibition of STAT3 induced growth 
arrest and apoptosis of tumor cells in vitro and tumor regression in vivo (Yue and Turkson, 
2008). Direct STAT3 inhibitors target the SH2 domain, the DNA binding domain or the N-
terminal domain. This disrupts either dimerisation, prevents binding to DNA or disturbs the 
transcriptional activity (Peibin Yue and James Turkson, 2008). STAT3 signaling can be 
targeted using various approaches: phosphopeptides (Turkson et al., 2001) and 
peptidomimetics (Turkson et al., 2004) which compete for binding, small molecules (Schust 
et al., 2006; Xu et al., 2009) blocking activity, siRNAs (Gao et al., 2005) that inhibit target 
gene expression and Decoy ODN (Naruya Tomita et al., 2003) which mimics the consensus 
sequence of the cis element as well as upstream inhibitors. So far, only one small molecule 
inhibitor and three oligonucleotide inhibitors are in the early preclinical stage (Peyser and 
Grandis, 2013) and more efforts will be necessary before patients can be treated with potent 
STAT3 inhibitors. 
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1.3. The nuclear receptor co-repressor 2 
(NcoRII/SMRT) 
1.3.1. Transcriptional repression 
A crucial cellular maintenance process is the restriction of gene expression by chromatin 
remodeling, DNA methylation and histone modifications. Co-repressors and co-activators 
have a major role in histone modifications. These modifications represent the histone code 
and include acetylation, phosphorylation, methylation, ADP-ribsylation, deamination, proline 
isomeration, ubiquitylation and sumoylation (Kouzarides, 2007). Co-repressors are usually 
recruited by transcription factors and act as scaffold proteins to recruit chromatin remodeling 
enzymes like HDACs and other repressive proteins (Perissi et al., 2010). The SMRT co-
repressor builds a core complex with mSIN3 and HDACs and interacts with key components 
of the transcriptional initiation process (Wong and Privalsky, 1998). These co-repressor 
complexes mediate the basal repression of genes by unbound nuclear receptors like the 
thyroid hormone receptor (TR) and retinoic acid receptor (RAR) (Yoon et al., 2003). 
1.3.2. Silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT) 
 
The nuclear receptor co-repressor 2 (NcoRII or SMRT) is a transcriptional co-repressor that 
plays a crucial role in many cellular processes. SMRT consists of a conserved bipartite 
nuclear-receptor-interaction domain (NRID) and three independent repressor domains that 
can actively repress a heterologous DNA-binding domain. Each NRID contains a CoRNR 
box motif (Jepsen and Rosenfeld, 2002a) (Fig. 1.6). 
 
Figure 1.6: Domain localisation of the nuclear co-repressor 2 (SMRT). The three repression 
domains are located in the N-terminal part of the protein. Between repression domain I and II two 
SANT domains are located. The C terminus contains the bipartite nuclear-receptor-interaction domain 
(NRID). Class II HDACs, the transcription regulator Pit-1 and the transcription factor STAT3 and Bcl-6 
bind to the repression domain III. 
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SMRT is a scaffold protein with 2525 amino acids in length that builds up multi-protein 
complexes with several other proteins like histone deacetylases, transcription regulators and 
factors e.g. HDAC3 (Li et al., 2000a), Pit-1 (Xu et al., 1998) and BCL-6 (Ahmad et al., 2003). 
Also, the signal transducer and activator and transcription (STAT3) is bound and repressed 
by SMRT in vivo (Ikeda et al., 2009). 
1.3.2.1. Functions of SMRT 
The promiscuous scaffold protein SMRT is involved in many cellular processes. The kind of 
action is usually not determined by SMRT itself but by the variation of different proteins in the 
co-repressor complex. The SMRT co-repressor complex can e.g. stimulate proliferation 
through repression of serum response factor (SRF), activator protein-1 (AP-1) and nuclear 
factor-B (NFB) (Lee et al., 2000). But it can also repress transcription by interaction with 
MAD, MyoD and HES-related repressor proteins (HERPs) (Jepsen and Rosenfeld, 2002a). 
SMRT has also a role in development and cell differentiation by interaction with Pit-1, Oct-1 
and the Notch-activated adapter protein Su(H)/RBP-J/CBF1 (Jepsen and Rosenfeld, 2002a). 
Via interaction with the transcription factor and oncoprotein BCL-6, SMRT is involved in 
apoptosis (Dhordain et al., 1998a). SMRT was also shown to interact with STAT5 (Nakajima 
et al., 2001a) and STAT3 (Ikeda et al., 2009) and therefore influences the immune response. 
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1.4. Intrinsically disordered proteins (IDPs) 
Both EBNA2 and SMRT are predicted to lack tertiary and much secondary structure, and are 
therefore not amenable to classical structural biology approaches. More generally, proteins 
can exist in three different states: completely folded, partially folded and completely 
disordered. Proteins in the latter two forms are referred as intrinsically disordered proteins 
(IDPs). About one third of all eukaryotic proteins and even over 70% of all cancer-related 
proteins are either completely disordered or have large segments that are intrinsically 
disordered (Xie et al., 2007). Viral proteins and especially herpesviruses are very rich in IDPs 
(Pushker et al., 2013). It is believed that the percentage of IDPs encoded in the genome 
increases with the complexity of the organism (Dunker et al., 2000). An explanation for this 
can be that IDPs evolve more rapidly and mutations occur more often because disordered 
regions are not constrained by their structure. A signature of intrinsic disorder is the 
presence of low sequence complexity and amino acid compositional bias exhibiting a low 
level of bulky hydrophobic and high level of polar and charged residues (Dyson and Wright, 
2005a). The lack of structure may provide a number of particular features and advantages 
(Gsponer et al., 2008): 
 Increased interaction area 
 Conformational flexibility to interact with several partner proteins 
 Possibility of folding-upon-binding 
 Accessible sites for posttranslational modifications 
 High abundance and accessibility of short linear interaction motifs  
 
IDPs may undergo interactions with many binding partners. The first interaction is in general 
unspecific and weak but leads to structural changes and a folding of the binding interface 
which allows a more specific, high affinity interaction. This two-step mechanism is called the 
“fly casting mechanism” (Sevcik et al., 2007a). The fastest and easiest way to predict intrinsic 
disorder is the use of disorder predictors e.g. RONN and IUPRED (Yang et al., 2005; 
Dosztányi et al., 2005). There are nearly 20 predictors available online and several 
metaservers (e.g. MeDoR (Lieutaud et al., 2008)) that aggregate the results of individual 
predictors to predict disorder with a very low error rate.  
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1.4.1. Disorder properties of EBNA2 
The amino acid composition of EBNA2 perfectly reflects the sequence features commonly 
found in IDPs. The sequence shows a low complexity indicated in particular by the large 
proline stretch ranging from aa 59-100 and the following arginine and glycine stretch which 
lies between the two transactivation domains (Cohen and Kieff, 1991). In addition, there is a 
high amount of negatively and positively charged amino acids attention as well as an 
absence of an obvious hydrophobic core.  
The disorder predictor IUPRED estimates the capacity of polypeptides to form stabilising 
contacts. It is assumed that structured proteins undergo a large number of inter-residue 
interactions, whereas IDPs do not have this capacity. The formalism used by IUPRED is 
based upon a 20 by 20 energy predictor matrix which involves the chemical property of one 
amino acid as well as the chemical properties of the surrounding amino acids to calculate the 
binding capacity for each amino acid. The disorder diagram for EBNA2 generated with 
IUPRED indicates that the protein is almost fully disordered (Fig. 7) as the probability for 
disorder is almost exclusively over the threshold of 50%.  
A new tool linked to IUPRED is ANCHOR which calculates the probability that a region within 
an IDP undergoes interactions with other proteins by estimating the feasibility that a given 
residue can form enough favourable interactions with globular proteins upon binding. The 
ANCHOR prediction for EBNA2 shows that the protein is predicted to undergo multiple 
interactions with several interaction domains distributed over the whole protein sequence 
(Fig. 1.7). The prediction could be verified by yeast-two-hybrid screens performed on the 
EBV-EBV and EBV-Human interactome (Calderwood et al., 2007) and by already known 
binding partners in the literature. 
 
Figure 1.7: Disorder prediction of EBNA2. Disorder (red line) and binding site (blue line) prediction 
diagram generated with IUPRED (http://iupred.enzim.hu/ 
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1.4.2. IDPs in malignancies 
Neither EBNA2 nor SMRT have been well studied at the structural level, however the 
importance of IDPs in various pathologies including cancer and neurodegenerative diseases 
is clear from other better understood systems. 
Disordered proteins are strongly linked to cancer due to their active roles in proliferation, 
apoptosis, cell cycle control and angiogenesis. The most prominent example is p53 which 
one of the mostly studied oncoproteins (Muller and Vousden, 2013). The tumor suppressor 
protein p53 is known as the “guardian of the genome” based on its broad spectrum of activity 
and ability to maintain genome integrity (Xue et al., 2013). Another example is BRCA1 which 
is mutated in many types of breast cancer. Like p53 BRCA1 is involved in many cellular 
processes including cell cycle control, transcription, stress response and the DNA damage 
response (Foulkes and Shuen, 2013). Both proteins, p53 and BRCA1, contain structured 
domains but also significantly disordered regions (Uversky et al., 2008). As a typical feature 
of IDPs they are very promiscuous and interact with multiple binding partners. STRING, a 
protein-protein interaction database, shows over 100 interaction partners for BRCA1 with a 
confidence score of at least 0.9. For p53 there are over 300 interacting proteins suggested.  
Another group of intrinsically disordered proteins is involved in neurodegenerative diseases 
like Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, and the prion 
disease (Dunker et al., 2008). A notable example is the microtubule associated protein tau 
which has been investigated extensively with regard to its disordered character. In healthy 
humans tau is intrinsically disordered. The partial transition from random coil to  structure 
followed by aggregation into paired helical filaments (PHFs) causes Alzheimer’s disease 
(Jeganathan et al., 2008). With just 11 suggested binding partners in STRING (confidence 
score >0.9) tau does not undergo as many interactions as p53 and BRCA1. Reasons might 
be that p53 and BRCA1 are transcription factors which interact with and can be modulated 
by multiple other proteins or that cancer related proteins are in general under more intense 
investigation. 
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1.5. Project origin and objectives 
In 2009, the same year I started my PhD work, two publications describing the competing 
interaction of the cellular IDP SMRT and the viral IDP EBNA2 with the cellular transcription 
factor STAT3 (Ikeda et al., 2009; Muromoto et al., 2009a). The authors describe how under 
physiological conditions SMRT bound STAT3 and suppressed its transcriptional activity. 
Upon transfection of cells with EBNA2 expression plasmids, the viral protein appeared to 
release SMRT from the complex resulting in enhanced STAT3 mediated target gene 
expression (Fig. 1.8). The hypothesis was that increasing STAT3 activity might be expected 
to enhance several immunosuppressive, pro-proliferative and anti-apoptotic effects in the 
host and might therefore prove to be a new and important survival strategy for Epstein-Barr 
virus.  
 
 
Figure 1.8: Interaction of SMRT and EBNA2 with STAT3according to (Ikeda et al., 2009; Muromoto 
et al., 2009a). Binding of SMRT to STAT3suppresses its transcriptional activity. EBNA2 releases 
SMRT from the complex and enhances STAT3 transcriptional activity. 
 
The interactions were studied in limited detail by co-immunoprecipitation experiments from 
total cell lysate and luciferase reporter assays. As this was the first description of the 
interaction between these three proteins the first task was to confirm the interaction in vitro 
from purified components. For this purpose an expression library of random fragments of 
EBNA2 was generated, and screened for expression of purifiable fragments. The interaction 
of SMRT-STAT3 and EBNA2-STAT3 could be confirmed by various complementary 
approaches (e.g. SPR, NMR and cell based assays). Next steps involved the identification of 
the approximate binding region in SMRT and EBNA2 interacting with STAT3. The interacting 
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SMRT fragment 39L23 was assigned by NMR and 3 regions involved in the STAT3 
interaction were identified. The STAT3-EBNA2 interaction was prioritised for detailed study 
due to its higher affinity and clearer mode of interaction, whilst the STAT3-SMRT remains to 
be characterised more fully in the future. The STAT3 interacting region of EBNA2 was 
mapped to a short span of amino acids and point mutants generated to confirm these data. 
The point mutants that are located within and close to conserved region 8 were tested for 
their effects in cell based assays. It was thus demonstrated that the point mutants not only 
disrupted the binding of EBNA2 to STAT3 in vitro (SPR, MST, NMR, pull-down and EMSA) 
but that the binding also disrupted in cells.  
In conclusion this work confirms the interaction between SMRT-STAT3 and EBNA2-STAT3, 
assigns the binding regions and their affinities using various biophysical methods. The 
kinetics of the binding were determined and preliminary data obtained that describe the 
effects of the disrupted binding in cells. This work thus addreses one piece in a puzzle, 
shedding light on the mechanisms by which Epstein-Barr virus hijacks the host organism. 
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Results 
Résumé 
Interaction de STAT3 avec l’activateur de transcription viral EBNA2 
La génération d’une banque d’expression de fragements d’EBNA2 à l’aide de la technologie 
ESPRIT est présentée. Les fragments obtenus couvrent les deux tiers de la partie C-
terminale du gène d’EBNA2 et s’expriment bien avec des rendements de l’ordre de 10 mg/l 
de culture bactérienne. La méthode de purification employée pour purifier les fragments 
d’EBNA2 (se répartissant sur différentes régions de la protéine) et le dimer de STAT3 est 
décrite. La protéine EBNA2 est principalement prédite intrinsèquement désordonnée. Ainsi 
des approches biochimiques et biophysiques ont été choisies pour caractériser EBNA2 en 
tant que proteine intrinsèquement désordonnée (IDP). Le fragment D9 de EBNA2 présente 
des caractéristiques de protéine intrinsèquement désordonnée tels qu‘ une plus haute 
sensibilité à l’activité de protéase, un retard de migration sur gel SDS-PAGE, une vitesse de 
rétention augmentée en chromatographie d’exclusion de taille et une résistance à la chaleur 
augmentée. Le caractère d’IDP du fragment D9 a également été caractérisé grâce à des 
enregistrements de spectres HSQC en RMN. Ce fragment D9 de EBNA2 interagissant avec 
STAT3 a été identifié par des expériences de résonance plasmonique de surface (SPR) et de 
pull-down. L’étude de l’interaction s’est poursuivie par des expériences de RMN. La cinétique 
d’interaction a été déterminée à l’aide d’analyses de MST et de SPR, permettant de mesurer 
une constante KD de l’ordre du nanomolaire. L‘attribution de pics de RMN combiné à un 
alignement de séquences d’homologues d’EBNA2 suggèrent que la région conservée (CR) 8 
correspond à la région d’interaction. Cette hypothèse a pu être vérifiée et confirmée grâce à 
des mutants de délétion. L’exacte région d’interaction a pu être définie grâce à des peptides 
portant une étiquette GST et de mutants (mutation ponctuelle) qui ont été soumis à des 
analyses de SPR. Des digestions protéasiques du complexe EBNA2-STAT3 suivies par des 
séquençages N-terminaux et des analyses de spectrométrie de masse ont suggéré que le 
site d’interaction avec l’ADN de STAT3 pouvait correspondre à la région d’interaction. 
Cependant des expériences EMSA ont montré que l’interaction de EBNA2 avec STAT3 
n’empêchait pas l‘intercation de STAT3 avec l’ADN. Des essais de cristallisation ont été 
effectués avec le complexe formé par STAT3 et le peptide synthétique d’EBNA2. Les cristaux 
obtenus diffractaient à une résolution de 6.5 Å, résolution insuffisante pour permettre de 
distinguer le peptide. L’interaction entre STAT3 et EBNA2 sauvage ainsi que des mutants 
ponctuels a été suivie en cellules de mammifère à l’aide du rapporteur luciférase de STAT3. 
L’activation de la voie de signalisation de STAT3 par les mutants d’EBNA2 a sévèrement été 
perturbée. Une perte générale de capacité de transactivation a été exclue grâce à des essais 
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avec le rapporteur CBF1. CBF1 est un autre facteur de transcription bien caractérisé activé 
par STAT3. 
Interaction d’EBNA2 avec d’autres protéines cellulaires 
Il a été montré que le domaine Mynd de BS69 interagissait avec la partie N-terminale 
d’EBNA2. De plus, deux motifs d’interaction PXLXP de EBNA2 (383-387 et 437-441) 
seraient les motifs impliqués dans cette interation. Des mutations simples et doubles ont été 
introduites (L385A et/ou L439A). Ces mutants ont ensuite été analysés par SPR, ce qui a 
permis de montrer qu‘une mutation simple de l’un des motifs PXLPX suffisait à totalement 
abolir l’interaction. Ainsi l’hypothèse publiée auparavant suggérant une redondance du motif 
ne pouvait pas être vérifiée par cette méthode. Il a précédemment été montré que Med25 et 
la protéine de Herpes simplex VP16 interagissaient ensemble. Des alignements structuraux 
de VP16 avec EBNA2 suggéraient que le site de liaison de EBNA2 était localisé entre les 
acides aminés 435 et 452, région couvrant la region conservée CR8. Des études dinteraction 
entre les fragments F3, A11, D9 d’EBNA2 et Med25 ont révélé que les fragments A11 et D9 
se liaient avec Med25 avec des affinités similaires. Cela suggère que la région d’interaction 
se situe plutôt au sein de la région où les deux fragments se chevauchent, couvrant la région 
CR7. 
Interaction de STAT3 avec le co-represseur cellulaire SMRT/NCoRII 
SMRT est une énorme protéine, qui avec ces 2525 acides aminés est significativement plus 
grosse que EBNA2. Pour réussir ce challenge, le gène de SMRT a été divisé au hasard en 6 
fragments qui ont été exprimés en cellules HEK293 et testés pour la suppression de la 
signalisation de STAT3 à l’aide du rapporteur luciférase de STAT3. Cette division au hasard 
était réalisable dans la mesure où il est alors possible de ne tenir compte d’aucune limite 
structurale. Par chance les fragments capables de suppression de signalisation de STAT3 
correspondaient à la région que couvrait la bibliothèque d’expression de fragments de SMRT 
préexistente au laboratoire. De deux fragments aves des localisations différentes sur SMRT, 
un fragment, 39L23 interagissait avec STAT3. La séquence d‘acides aminés de 39L23 a été 
assignée par RMN. Trois régions (79-89, 106-127 et 162-173) étaient principalement 
affectées par l’interaction. Des mutants de délétion de ces régions n’ont montré aucun effet. 
Seule la délétion de deux régions couvrant les acides aminés 79-127 ont montré une 
augmentation de l’affinité de liaison avec un changement de mode d’interaction d’un mode à 
2 étapes à un mode d’interaction 1:1, la constante KD déterminée pour l’interaction 39L23-
STAT3 passant de 120 nM à 20 nM. L’interaction de 39L23 à STAT3 ne provoque pas la 
libération de STAT3 de l’ADN, comme montré par EMSA, mais réprime l’activité de STAT3 
par le recrutement d’autres enzymes de répression comme par exemple les HDACs. 
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2.1. Interaction of STAT3 with the viral transcriptional 
activator EBNA2 
 
Under physiological conditions STAT3 is bound by the nuclear co-repressor SMRT (Ikeda et 
al., 2009). Upon infection, the complex between the two cellular proteins, STAT3 and SMRT 
is disrupted by the Epstein-Barr virus protein EBNA2. EBNA2 was shown to somehow 
release SMRT from this complex and to enhance the transcriptional activity of STAT3 (Ikeda 
et al., 2009). EBNA2 therefore enhances the transcription of both host and viral STAT3 
regulated genes. STAT3 activity has several immunosuppressive effects in the host 
organism (Kortylewski et al., 2005a, 2009; Berg et al., 1996; Gerosa et al., 2008) and may 
therefore be of importance for the viral survival strategy of Epstein-Barr virus (Koganti et al., 
2013). Viruses use numerous different mechanisms to hijack host cell functions, including 
commonly the mimicking of natural interaction motifs (Davey et al., 2011, 2012). The IDP 
characteristics of both EBNA2 and SMRT suggest that this may be the mechanism EBV uses 
to hijack STAT3 function, thereby manipulating the host cell immune system to establish a 
lifelong alliance with the host organism.  
This results presented here detail (1) the generation of highly expressing, recombinant 
protein fragments of EBNA2 (ESPRIT library), (2) characterisation of the STAT3-EBNA2 
interaction, (3) mapping of the binding region to individual amino acids, and (4) effects of 
disrupted binding in cells.  
2.1.1. Generation of highly expressing and well behaving 
EBNA2 constructs 
2.1.1.1. Overview ESPRIT technology 
To date there has been no recombinant expression of EBNA2 reported. We hypothesise that 
this may be because EBNA2 is an intrinsically disordered protein (IDP) and this class of 
proteins often cannot be expressed full length in recombinant systems. IDPs are 
characterised by their low sequence complexity, absence of bulky hydrophobic amino acids 
necessary for formation of a hydrophobic core and a high content of polar and charged 
amino acids (Dyson and Wright, 2005a). In order to obtain fragments of a size and yield 
suitable for biophysical studies a new approach was taken which promises to be an effective 
and time saving alternative to the classical construct designe/PCR cloning approach. An 
expression library of random EBNA2 gene fragments encoding polypeptides from the C- 
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terminal two-thirds of the protein (after the polyproline stretch) was generated using the 
ESPRIT technology (Yumerefendi et al., 2010, 2011). ESPRIT is an approach to obtain 
soluble protein fragments in high quantities from poorly understood/annotated targets (Fig. 
2.1) by screening for constructs that are compatible with the host organism being used for 
expression. Thus a design step is unnecessary as it is substituted by an experimental 
search. It generates random fragment libraries of about 28,000 clones which are tested for 
in-frame soluble expression in a fluorescent colony blot format. All clones are ranked 
according to signal intensity for both tags, the N-terminal His tag and the C-terminal biotin 
tag with the signal from the latter predicting solubility. The 96 most promising clones are test 
purified with NiNTA affinity chromatography and purity, degradation and expression level 
then assessed by SDS-PAGE. Typically, the 24 best expressing clones are sent for 
sequencing to determine the construct boundaries that afford stable soluble expression. 
    
Generation of an EBNA2 expression library (see 4.2.2) 
The sequence of the synthetic EBNA2 gene used in this study was derived from the 
laboratory strain B95-8 that has been most studied and belongs to the EBV-1 subtype group. 
The codon optimised gene (Geneart; appendix) was cloned into the library vector 
pESPRIT002 which encodes an N-terminal 6xHis tag and a C-terminal biotin acceptor 
peptide (BAP). The restriction enzymes AatII/AscI (5’ end) and NotI/NsiI (3’ end) were used 
to generate 5’ overhangs on the gene side and the gene was digested sequentially from both 
ends using exonuclease III that digests 5’overhangs, but not 3’. The remaining single strand 
was removed using mung bean nuclease and polished by Pfu polymerase treatment. The 
plasmids were then recircularised by ligation and recovered by transformation in Mach1 cells. 
After transformation into expression strain BL21 AI RIL the truncated expression clones were 
plated on LB agar plates and around 28,000 colonies (72 x 384 well plates) picked using 
automated robotics. The expression of constructs bearing the 6xHis tag and BAP was 
analysed by colony blot (Appendix Fig A.2) and ranked according to signal intensity. The 96 
best clones were analysed by purification and SDS-PAGE (Fig. A.3) and the 24 best 
expressing clones further analysed by DNA sequencing of the EBNA2 gene inserts. 
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Figure 2.1: EBNA2 fragment library generation. The EBNA2 expression vector pESPRIT002 
encodes an N-terminal 6xHis tag and a C-terminal biotin acceptor peptide (BAP). The restriction 
enzymes AatII/AscI (5’ end) and NotI/NsiI (3’ end) were used to generate 5’ overlapping ends and the 
gene was digested sequentially from both ends using exonuclease III. Around 28000 colonies were 
picked from LB agar plates using automated robotics. The expression of the 6xHis tag and BAP were 
analysed by colony blot and ranked according to signal intensity. The 96 best clones were analysed 
by SDS-PAGE and out of these the 24 best expressing clones were further analysed by sequencing. 
 
Three clones were chosen according to location in the gene and soluble expression level 
(Fig. 2.2). Using a naming convention common in library experiments, fragments were 
named according to their position in the final 96-well plate that was prepared as a glycerol 
stock. Fragment F3 comprises aa 161-296, fragment A11 from 294-399 and the C-terminal 
fragment D9 344-475. The application of a random library method (ESPRIT) to IDPs is a new 
approach and here allowed us to obtain well-behaving sub constructs of a poorly annotated 
target where domain identification algorithms were of no use due to the absence of folded 
domains.  
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Figure 2.2: EBNA2 fragments cover the C-terminal two-thirds of the EBNA2 gene. Dim = 
dimerisation domain, Pro = Proline stretch, RBP-J binding region, ArgGly = arginine glycine rich 
region, TAD = transactivation domain, NLS = nuclear localisation signal. 
 
2.1.2. Expression and purification of recombinant protein 
2.1.2.1. Expression and purification of the STAT3 homodimer 
Dimerisation of STAT3 requires phosphorylation of Tyr705 in the SH2 domain. Therefore 
STAT3 (127-722) was expressed in E. coli TKB1 cells that coexpress a tyrosine kinase which 
phosphorylates the SH2 domain of STAT3 (Becker et al., 1998a). As a control STAT3 was 
also expressed in regular BL21 cells but appeared unstable, suggesting that in the absence 
of phosphorylation the monomeric form does not fold into a stable form in E. coli. Expression 
and purification were performed according to the published protocol (Becker et al., 1998a). 
Gel filtration analysis was performed to determine if the protein was actually in the dimeric 
state. According to the elution profile STAT3 (127-722) was expressed as a dimer (Fig. 2.3). 
The purification was assessed by 12% SDS-PAGE revealing a total amount of 5 mg of at 
least 95% pure STAT3 dimer per litre of bacterial culture that could be concentrated to 5 
mg/ml. 
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Figure 2.3: Gel filtration profile of STAT3 (127-722) expressed in E. coli TKB1 cells. The 
preparative column Superdex200 26/60 GL was used. The protein eluted at a volume of 185 ml which 
consistent with a 130kDa (dimer) complex. Elution fractions were loaded on a 12% SDS-PAGE. 
2.1.2.2. Expression and purification of EBNA2 fragments 
After deletion of the BAP that was only needed for the solubility screening procedure, the 
expression of the most interesting clones was scaled up. E.coli strain BL21 AI (Invitrogen) 
was used for expression and transformed as in earlier experiments. Bacteria were grown in 1 
l LB medium and protein expression was induced at an OD600nm of 0.6 when the expression 
temperature was lowered to 25 °C. Lysis was performed by ultrasonication and the soluble 
fraction incubated with NiNTA beads. After the first affinity chromatography purification the 
fractions with the highest purity were pooled and the tag was removed with TEV protease 
(Fig. 2.4). In order to remove the high concentration of imidazole in the elution buffer the 
proteins were dialyzed against washing buffer, then incubated with NiNTA beads again to 
remove the 6xHis tag and the 6xHis tagged TEV protease. Fragments F3 and D9 were 
obtained at acceptable purity using affinity chromatography but for fragment A11 it was 
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necessary to perform a further purification step. Size exclusion chromatography was used to 
remove contaminants resulting in a total purity of around 90%. The total amount of protein 
per litre of bacterial culture for each construct was about 10 mg (Fig. 2.5).  
 
Figure 2.4: Expression and affinity purification of EBNA2 fragments A: EBNA2 fragment F3, B: 
EBNA2 fragment A11 and C: EBNA2 fragment D9 Abbreviations: M: Molecular weight marker, IS: 
Insoluble fraction, S: Soluble fraction, FT: Flow through, W: Wash, F1-10: Elution fractions 1-10. 
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Figure 2.5: Size exclusion chromatography of EBNA2 fragments A: EBNA2 fragment F3, B: 
EBNA2 fragment A11 and C: EBNA2 fragment D9. Elution profile using an analytical superdex S75 
10/300 column and peak fractions loaded on 15% SDS-PAGE.  
 
 
All three EBNA2 fragments showed characteristic behaviors of IDPs regarding running size 
in SDS-PAGE and elution profile in size exclusion chromatography (Table 2.1), but were 
confirmed as correct by mass spectrometry. 
 
EBNA2 fragment 
Predicted size 
and size in mass 
spec (kDa) 
Approximate size 
in SDS-PAGE 
(kDa) 
Size in gel 
filtration (kDa) 
F3 14.70 (14.70027) 25 13.4 
A11 11.33 (11.33543) 18 28.6 
D9 14.36 (14.36748) 25 32.9 
 
Table 2.1: Predicted and experimental size of the EBNA2 fragments. Sizes predicted using ExPASy 
ProtParam tool, experimentally measured by mass spectrometry, estimated from 15% SDS-PAGE 
running behavior and calculated from elution volume in size exclusion chromatography using a 
superdex S75 10/300 column. 
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2.1.3. Structural characterisation of the IDP EBNA2 
EBNA2 is predicted to be intrinsically disordered which applies to about one third of all 
eukaryotic proteins and 70% of cancer-related proteins. This characteristic is particularly 
common in many viral families, with the IDP content of herpersviruses being 17% (Pushker 
et al., 2013). These proteins are either fully disordered or have large (> 40 amino acids) 
segments (Galea et al., 2008) and our understanding of how these proteins function is 
limited.  
2.1.3.1. Biochemical characterisation of EBNA2 
IDPs have an increased interaction area with easily accessible modification sites and 
frequently interact with binding partners via short linears motif (Tompa, 2012). This lack of 
structure imparts a high conformational flexibility and the possibility of folding-upon-binding, 
or at least the formation of local structure at interfaces. Characteristics of an IDP sample are 
1) higher sensitivity to protease treatment; 2) aberrant migration in SDS-PAGE; 3) increased 
hydrodynamic radius resulting in rapid elution during size exclusion chromatography; 4) 
increased heat resistance. 
 All protein fragments used in this study (EBNA2 fragments F3, A11 and D9 as well as SMRT 
fragment 39L23) migrate abberantly on SDS-PAGE and show a premature elution profile in 
size exclusion chromatography (Fig. 2.4 and 2.5). In contrast, the structured protein STAT3 
runs in predicted size in SDS-PAGE and elutes in the predicted volume during size exclusion 
chromatography (Fig. 2.3).  
EBNA2 D9 shows extreme heat resistance being stable at temperatures up to 90°C, whereas 
STAT3 is almost completely insolubilised at this temperature (data not shown).EBNA2 D9 is 
rapidly degraded during protease treatment (data not shown). 
2.1.3.2. Biophysical characterisation of EBNA2 
It is self-evident that the structure of an unstructured protein cannot be solved by x-ray 
crystallography, although in some cases a certain conformation might be favoured by crystal 
packing resulting in a structure with questionable biological significance. On the other hand, 
binding to a globular binding partner causes a local ordering of the IDP at the interface, or 
even acquisition of some level of fold of the IDP; this could potentially yield a biologically 
relevant structure that may crystallise. 
A more widely used method to study the interaction of IDPs with their partner proteins is 
protein NMR spectroscopy (Fig. 2.8). With NMR it is not only possible to obtain structural 
information about a protein but also study the dynamics of its interactions. For assignment 
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experiments double labelled proteins are required (usually 15N and 13C) which allow the 
record of triple resonance experiments. The obtained parameters are then used to calculate 
a structure (Cavanagh et al., 2007). An example of the structure determination of an IDP 
binding to partner proteins by NMR is the viral protein VP16 which gains structure while 
binding to TFIIB and PC4 (Jonker et al., 2004). The recording of a HSQC spectrum of a 
single labelled protein can show if it is structured or not. The chemical shifts of the amide 
protons on the x-axis depend directly on the secondary structure of a protein which results in 
a narrower peak distribution on the x-axis for unstructured proteins.  
2.1.4. Interaction between EBNA2 and STAT3 
EBNA2 is a small protein of 487 aa, but was found to undergo interactions with many cellular 
host and viral proteins in a large scale interaction screen (Calderwood et al., 2007). IDPs 
commonly interact with target proteins via short linear motifs (Davey et al., 2011) which can 
be high affinity in themselves (e.g. NLS peptides interact with low nanomolar affinities (Boivin 
and Hart, 2011) Alternatively, a first, relatively weak contact may occur following which the 
protein rearranges into a higher ordered, structured conformation to permit a strong and 
specific interaction (Dyson and Wright, 2005a; Sugase et al., 2007a). A series of 
experiments were thus performed to characterise the nature of the EBNA2-STAT3 
interaction. 
2.1.4.1. Binding analysis by surface plasmon resonance and pull-
down experiments 
 
All three EBNA2 fragments were analysed by surface plasmon resonance (SPR) for binding 
to STAT3. Because of its size and the dimeric character of STAT3, the EBNA2 fragments 
were immobilised, since dimeric STAT3 would be expected to dissociate leaving a chip-
bound monomer. All EBNA2 proteins were immobilised in different flowcells of the same 
sensor chip at equal levels (~2000 RU). STAT3 was injected as analyte at two different 
concentration ranges: 1-100 nM and 125-1000 nM. Independent of the concentration range 
used fragment A11 did not bind STAT3, whereas fragments F3 and D9 interacted (Fig. 
2.6A). No binding was observed to the chip surface in the underivatised flow cell. This result 
was then confirmed by pull-down experiments (Fig. 2.6B) where biotin-tagged EBNA2 
fragments were bound to streptavidin magnetic beads and incubated with E.coli lysate 
containing recombinantly expressed STAT3. After several washing steps, proteins were 
eluted from the beads by boiling and analyzed by 12% SDS-PAGE. Proteins were blotted on 
a nitrocellulose membrane and detected by STAT3 antibody and Alexa 488-conjugated 
streptavidin. Fig. 6B shows that STAT3 was bound and pulled down by EBNA2 fragments F3 
and D9 but not by the empty beads or EBNA2 fragment A11. 
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Figure 2.6: Comparative binding studies of EBNA2 fragment F3, A11 and D9 to STAT3. A: 
Comparison of EBNA2 fragment F3, A11 and D9 binding to STAT3 at a single injection of 1 M. B: 
Pull-down of EBNA2 fragments F3, A11 and D9 via biotin tag together with STAT3 from E.coli lysate. 
Left blot detection of STAT3 via STAT3 antibody and right loading control detection of biotin tagged 
proteins via streptavidin Alexa-488. 
 
By SPR, D9 and F3 bound STAT3 with the respective affinities of KD=7.6 nM (Fig. 2.7A) and 
KD=240 nM (Fig. 2.7B). KD values were obtained using the BIAevaluation software and 
sensorgrams were fitted using a two-state model (see 4.3.1). This was necessary because a 
1:1 Langmuir model did not fit the data and it has been reported in other system studies that 
the two-state model best describes IDP interactions (Sevcik et al., 2007a) where there is an 
initial reversible fast encounter and then a slow rearrangement into a stable binding 
conformation. We thus assumed that fragments F3 and D9 bound to STAT3 via such a two-
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step mechanism and may therefore conform to a “fly casting mechanism” whereby weak 
reversible initial interactions influence the probability of a structural rearrangement into a tight 
complex (Sugase et al., 2007a).  
 
 
Figure 2.7: A: Sensograms with fitted curves (in black) of STAT3 binding to D9 (concentration range 
of injected STAT3: 25-100 nM) and B: alternative thermodynamic evaluation method applied to the 
same data within the linear concentration range. C: Sensograms and fitted curves (in black) of STAT3 
binding to F3 (concentration range of injected STAT3: 125-1000 nM) and D: thermodynamic analysis. 
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2.1.4.2. Binding analysis by high field nuclear magnetic resonance 
(NMR) 
 
Due to its significantly higher binding affinity, fragment D9 was studied further to confirm 
specific binding was occurring and characterise in detail the binding region. Heteronuclear 
Quantum Coherence (HSQC) spectra of 15N labelled D9 alone and in complex with 
unlabelled STAT3 in a 1:1 ratio were recorded in collaboration with the Blackledge lab (IBS, 
Grenoble). HSQC spectra show the correlation between nitrogens on the y-axis and amide 
protons on the x-axis. Each peak in the spectrum corresponds to one amino acid with the 
exception of prolines that are invisible as they lack amide protons (Cavanagh et al., 2007). 
For D9 alone, the narrow peak distribution on the x-axis from 7-8.5 ppm indicated that this 
fragment was intrinsically disordered since structured proteins usually show a peak 
distribution from 6.5 – 9.5 ppm. This observation is in agreement with bioinformatic 
predictions (IUPRED, RONN and others) and further supports the choice of model used to 
analyse data during the SPR experiments (Fig. 2.7). The absence of β-strands and α-helices 
in EBNA2 fragment D9 was later confirmed by circular dichroism (data not shown). 
The comparison of NMR parameters of the free and STAT3-bound state of D9 revealed 
significant changes. Some peaks in the complex spectrum weakened or disappeared, other 
peaks shifted (Fig. 2.8) which was a clear indication for STAT3 binding. Shifting peaks 
indicate a conformational change and vanishing peaks indicate changes in the dynamic rate 
of the protein. STAT3 is significantly larger than the EBNA2 fragment D9. Therefore the 
region in D9 binding to STAT3 tumbles in the same speed as STAT3 thus causing weaker 
and vanishing peaks in the spectrum. 
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Figure 2.8: NMR spectra of D9 alone (black) and D9-STAT3 complex (green) upon titration of STAT3. 
The fragments were labelled with 
15
N and measured at a concentration of above 200 M in a volume 
of 250l. The ratio between D9 and STAT3 was 1:1.  
 
2.1.5. Identification of the STAT3 binding region in EBNA2 
The assignment of the HSQC spectrum was not performed because of the quality of the data 
and time constraints. Nevertheless, some specific amino acids like glycine, asparagine, 
glutamine, serine and tryptophan are readily distinguished in a HSQC spectrum without 
assignment. Therefore alignments were used to deduce the possible binding region in 
EBNA2 relative to conserved regions (CR). Since fragment A11, which overlaps with the N-
terminal half of fragment D9, does not bind STAT3, only amino acids 400 to 475 were 
considered to be involved in STAT3 binding. The C-terminal sequence of D9 was aligned 
with the sequences of EBNA2 homologues (human EBV type 1 and 2, baboon LCV and 
rhesus LCV) and a region of interest defined corresponding to CR8 (Fig. 2.9). Also, two of 
three tryptophans within protein fragment D9 vanished and weakened respectively and two 
tryptophans could be located within and in close proximity to CR8. In total EBNA2 comprises 
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9 CRs whereas CR1-4 can be found in the N-terminal region and are associated with self-
assembly (Harada et al., 2001). Separated from CR1-4 by the “diversity region” are CR5-9 
which are located in the C-terminal part of the protein; these are associated with transcription 
regulation (Cancian et al., 2011).  
 
Figure 2.9: Sequence alignment of EBNA2 with indication of CR1-9 and location of the library 
fragments. Comparison with EBV type 1 and 2, baboon LCV and rhesus LCV reveals 2 CRs in 
fragment D9. 
To test this hypothesis from sequence alignments a deletion mutant lacking CR8 was 
generated by overlap extension PCR and tested for binding to STAT3 by SPR and 
microscale thermophoresis (MST) (Fig. 2.10). For SPR experiment, D9 wt and D9CR8 were 
immobilised on a CM5 chip at equal levels (2500 RU) and STAT3 was injected at different 
concentrations with a maximum concentration of 1 M. D9CR8 did not show any binding at 
any given concentration.  
As the binding analysis of the SPR data using the two-state evaluation model is more 
complicated than a simple 1:1 binding mode, it was desirable to complement this binding 
analysis approach with another one. MST is a relatively new method which measures 
motions of proteins in microscopic temperature gradients and detects thermophoretic 
changes in conformation, charge and size. As such, it is ideal for measuring protein-protein 
interactions (Jerabek-Willemsen et al., 2011). In contrast to SPR it is a free solution method 
comparable with ITC (Wienken et al., 2010), but with far lower sample requirements. For the 
MST experiment STAT3 was fluorescently labelled with an amine reactive dye (see 4.3.2 for 
more detail).  
 
45 
 
Both methods showed that the deletion mutant CR8 abrogates binding to STAT3. The KD 
obtained by MST was 70 nM; almost 10 times higher than the value obtained by SPR. This 
difference can be explained by the different methods of KD calculation. The BIAevaluation 
software calculates the KD using a 2 step kinetic model which takes fast and slow 
association/dissociation into account (see 4.3.1 for more detail) whereas MST measures 
mobility differences between free and saturated binding. Nevertheless, both values are in the 
lower nanomolar range and point to a highly specific binding event, consistent with the NMR 
results. 
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Figure 2.10: Comparison of fragment D9 wild-type and D9CR8 binding to STAT3 A: SPR 
analysis at a single injection of 100 nM. B: MST analysis with a STAT3 concentration range of 10 M 
to 0.3 nM. 
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2.1.6. Identification of EBNA2 residues involved in the 
binding to STAT3 
 
In order to identify individual amino acids that mediate STAT3 binding, alanine mutants were 
generated using the QuikChange mutagenesis strategy (Stratagene). The alanine scan of 
CR8 sampled all amino acids except prolines. All mutants were tested for binding to STAT3 
by SPR and MST. One mutant, Ser448 in CR8, showed a significantly reduced binding 
affinity. A synthetic peptide composed of the amino acid sequence of the minimal CR8 motif 
was ordered and tested for binding using MST (Table 2), however no binding was observed 
suggesting an involvement of further amino acids flanking regions of CR8. Therefore, several 
GST fusion peptides containing CR8 plus additional sequence N- and/or C-terminal to CR8 
were cloned and expressed. To measure binding, the GST tagged peptide was captured on 
a Biacore CM5 chip with immobilised GST antibody (Hutsell et al., 2010) and STAT3 injected 
in different concentrations. The results showed that the amino acids located on the N-
terminal side of CR8 are not required for binding whereas deletion of the C-terminal amino 
acids diminished or abolished binding, thereby demonstrating that CR8 plus 12 amino acids 
on the C-terminus are essential for the binding to STAT3 (Table 2.2). 
 
 
Peptide name Sequence 
Binding 
affinitiy 
D9TA-FL IHEPESHNSPEAPILFPDDWYPPSIDPADLDESWDYIF +++ 
D9TA-1   PESHNSPEAPILFPDDWYPPSIDPADLDESWD + 
D9TA-2 HNSPEAPILFPDDWYPPSIDPADLDE - 
D9TA-3 IHEPESHNSPEAPILFPDDWYPPSIDPADLDESWD + 
D9TA-4 IHEPESHNSPEAPILFPDDWYPPSIDPADLDE - 
D9TA-5       PESHNSPEAPILFPDDWYPPSIDPADLDESWDYIF +++ 
D9TA-6              HNSPEAPILFPDDWYPPSIDPADLDESWDYIF +++ 
CR8                             PILFPDDWYPPSI - 
 
Table 2.2: Sequence and STAT3 binding affinity of GST-EBNA2 fusion peptides. EBNA2 peptide 
sequence (amino acids of CR8 are indicated in bold and underlined). 
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The alanine screen was extended to the C-terminal amino acids and all point mutants, the 
wild-type D9 protein as a positive control and the CR8 deletion mutant as a negative control 
were analysed by SPR and MST. Four mutations showed the greatest effects and a strongly 
reduced binding affinity: S448A, W458A, D459A and Y460A (Table 2.3). 
 
Mutant Binding capacity 
Wild-type +++ 
CR8 - 
I438A +++ 
L439A +++ 
F440A +++ 
D442A ++ 
D443A ++ 
W444A +++ 
Y445A +++ 
S448A + 
I449A +++ 
W458A + 
D459A + 
Y460A + 
F462A +++ 
 
Table 2.3: Location of the mutation in EBNA2 fragment D9 and binding capacity. Critical amino acids 
are indicated in bold. 
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2.1.7. Identification of the EBNA2 binding region in STAT3 
The STAT3 binding site of EBNA2 was thus identified and critical residues determined. To 
identify the complementary EBNA2 binding region on STAT3, the STAT3 homodimer, 
EBNA2 fragment D9 and the complex of D9 and homodimeric STAT3 were digested with 
trypsin, elastase and chymotrypsin. The digestion patterns were compared to identify 
protected regions of STAT3. After digestion with trypsin two fragments (one protected and 
the other one not) were visible and analysed by N-terminal sequencing and mass 
spectrometry (J.-P. Andrieu & L. Signor, IBS). For this, single proteins and complex were 
digested for 5, 15, 30 and 60 min at 21 °C. The digest was stopped by addition of Laemmli 
buffer to the samples and heating to 95 °C. Aliquots were electrophoresed on 12% SDS-
PAGE and protein fragments were visualised by Coomassie blue staining. For N-terminal 
sequencing, the fragments of interest were transferred to a PVDF membrane, whilst for mass 
spectrometry analysis frozen aliquots containing all protein fragments plus peptidase were 
analysed. Both were found to have the same N-terminus but different C-termini suggesting 
that this is the binding region. Fig. 2.11B shows the location of the putative ENBA2 binding 
region of STAT3; it is located in a loop in the DNA binding domain. 
 
 
Figure 2.11: A: Digestion pattern of the STAT3-D9 complex and location of the binding 
region within the STAT3 dimer. Digest with 30 ng trypsin of D9 (60 g), STAT3 (20 g) and 
STAT3-D9 complex at different time points and at 21
°
C. Protein fragments marked with a black 
box were analysed by N-terminal sequencing and mass spectrometry. B: The combination of N-
terminal sequencing and mass spectrometry suggests a possible binding side for EBNA2 
fragment D9 in STAT3 (pink sticks). PDB: 1BG1. 
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2.1.8. Binding of EBNA2 D9 does not prevent DNA binding 
This raised the question of whether EBNA2 prevents DNA binding by STAT3. In order to test 
this hypothesis a STAT3-DNA electromobility shift assay (EMSA) was performed using 
fluorescent oligos. Purified STAT3, labelled target site oligo and/or wild-type or CR8 D9 
protein were incubated for 30 min and electrophoresed on a 6% native polyacrylamide gel 
(Fig. 2.12). Lanes 2-4 show that STAT3 binds DNA but EBNA2 does not. Lanes 5-7 show 
the STAT3-EBNA2 D9 complex binds DNA albeit with a different mobility and suggests a 
binding ratio of 1:2 (1 dimer STAT3: 2 D9). Protein D9CR8 does not seem to interact with 
STAT3 when used at the same concentrations as D9 (lanes 8-10).  
 
Figure 2.12: EMSA of STAT3, D9 and D9CR8 as well as STAT3-D9 and STAT3-D9CR8 
complexes in different ratios bound to STAT3-binding oligo labelled with Alexa488. Protein-DNA 
complexes were run on a 6% native gel for 2 h at 4
°
C. Ratios of D9 and D9CR8 in relation to a 
STAT3 dimer (STAT3:D9): + = 1:1, ++ = 1:2, +++ = 1:4.  
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2.1.9.  First crystallisation trials 
First crystallisation trials were carried out in the hope of solving the crystal structure of the 
STAT3-EBNA2 complex. Crystallisation drops were set up robotically at the EMBL 
crystallisation service (HTX lab, EMBL Grenoble). STAT3 homodimer at 5 mg/ml was mixed 
with DNA alone and with DNA and the binding peptide D9TA-6 (see Table 2). In total, 576 
crystallisation solutions were tested with drops of 100 nl volume were set robotically using 
the sitting drop method at room temperature. Over 70 crystallisation conditions resulted in 
crystals of mainly bi-pyramidal shape in the size of 40-100 m (Fig. 2.13 A + B). The growth 
time ranged from 1-7 days. 
Four data sets were collected at the PROXIMA I beamline (SOLEIL, Paris) with a maximum 
resolution of 6.5 Å (Fig. 2.13C). The resolution would not suffice to see the peptide in the 
structure. 
 
Figure 2.13: Crystals and diffraction pattern of STAT3 homodimer and EBNA2 binding peptide. 
Crystals obtained in A: 0.8 M ammonium sulphate and 0.1M MES pH6 and B: 25% ethylene glycol, C: 
Diffraction pattern with 6.5 Å resolution. 
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2.1.10. Cellular assays investigating the STAT3-EBAN2 
interaction 
 
Prior to this work, the interaction between STAT3 and EBNA2 had been described using 
luciferase-STAT3 promoter assays and co-immunoprecipitation (Ikeda et al., 2009; 
Muromoto et al., 2009a) with no indication of binding regions or affinities. Here we were able 
to obtain recombinant proteins to study the interaction in vitro using various biophysical 
methods and determine binding affinities, the binding region and crucial amino acids. 
Furthermore, EBNA2 could be characterised structurally by NMR. It was thus desirable to 
study the interaction again in cell based assays to see whether the point mutations of EBNA2 
that affected the STAT3 interaction in vitro show effects in vivo. 
2.1.10.1. Generation of stable cells expressing the luciferase gene 
under a STAT3 promoter element 
 
Lentiviral particles are widely used tools to generate stable cell lines (Matrai et al., 2010) and 
permit the gene of interest to be stably inserted into the cellular genome. A STAT3-luciferase 
HEK293 cell line was generated using lentiviral particles carrying the firefly luciferase gene 
under a STAT3 promoter. After transfection cells were kept under puromycin selection 
pressure and single cells isolated using the limiting dilution method to obtain a stable, 
monoclonal cell line. The generation of monoclonal cell lines is required to exclude the 
possibility that observed changes might be caused by the genome integration and not 
directly by modulation of the STAT3-EBNA2 interaction. Leukaemia inhibitory factor (LIF), an 
activator of STAT3-signaling, was used to challenge the cells and to stimulate STAT3 
signaling. 
Cells were transfected with the KG172 full-length EBNA2 expression plasmid in increasing 
concentrations to confirm a dose-dependent effect and identify the concentration of plasmid 
that could be used to test mutants (Fig. 2.14A). Consequently, the S448A and CR8 EBNA2 
mutants were analysed at a constant concentration (Fig. 2.14B) and in the context of the full-
length protein. Dose dependent activation of STAT3 signalling by EBNA2 expression was 
observed (Fig. 2.14A), consistent with previous data using transient transfections (Muromoto 
et al., 2009a). Differences in the activation potential of STAT3 between EBNA2 wild-type and 
mutants were measurable (Fig. 2.14B). 
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 Figure 2.14: Luciferase assay of EBNA2 and EBNA2 binding mutants. A: Stably transfected 
HEK293-STAT3-Luc cells were co-transfected with increasing concentration of full-length EBNA2 
expression plasmid (KG172). After 24 h, cells were treated with 100 ng/ml of LIF for 6 h. Luciferase 
signals were detected using a Wallac luminometer. B: Using the same method cells were transfected 
with a concentration of 100 ng wild-type EBNA2, S448A and CR8. 
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Deletion of CR8 in EBNA2 reduced STAT3 activation by around 50% (p-value for KG172wt 
compared with KG172CR8 < 0.01). Substitution S448A in CR8 reduced the activation of 
STAT3 by around 25% (p-value for KG172wt compared with KG172 S448A < 0.36). These 
results confirmed the importance of CR8 for binding to STAT3 but the standard deviation 
values, especially for the most interesting in vitro mutant S448A, were rather high; however 
despite repeated attempts the data remained similar. 
2.1.10.2. Studying the STAT3-EBNA2 interaction by transient 
transfection 
 
In order to obtain better statistics and to study the STAT3-EBNA2 interaction in a B cell line 
environment which is closer to the natural host of EBV, a transient transfection approach was 
performed in DG75 cells, a human B lymphocyte cell line. The following experiments were 
performed during an EMBO short term fellowship visit to the laboratory of B. Kempkes, 
Helmholtz institute, Munich. 
Initially, the expression of the different EBNA2 expression constructs in DG75 cells was 
confirmed by western blot (Fig. 2.15). All constructs were expressed but at different levels 
with EBNA2 mutants Y460A-W458A-D459A (triple mutant) and S448A having the highest 
expression level. It is not clear what causes the difference in running behavior (the 
constructs were all sequence verified). A possible explanation might be that the point 
mutants might affect certain migration-influencing posttranslational modifications or that the 
deletion of CR8 might change the charge of the protein leading to aberrant migration. 
However, because of time constraints the repetition of the experiment was not possible (but 
is planned). 
 
Figure 2.15: Expression of EBNA2 wild-type and mutants in DG75 cells. A: Detection of HA 
tagged EBNA2 wild-type and mutants using HA antibody. B: Detection of GAPDH in total cell lysate as 
a loading control. Legend: M: Ladder, 1: Empty vector, 2:EBNA2 wt, 3: EBNA2 S448A, 4: EBNA2 
Y460A-W458A-D459A, 5: EBNA2 S448A-W458A-D459A, 6: EBNA2CR8.                                  
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To measure the transactivation activity of EBNA2 mutants, DG75 cells were transfected with 
a plasmid containing the luciferase gene under control of a STAT3 promoter element in a 
similar manner to that performed in the lentivirus experiment (Fig. 2.14). The luciferase signal 
reports the activation of STAT3 by EBNA2. A concentration series of EBNA2 wild-type 
plasmids was used to determine the sensitive range of the assay, and then a constant 
concentration of point mutant expression plasmids was used to co-transfect cells. 
After performing the experiment several times with varying LIF and IL-6 concentrations we 
concluded that the particular DG75 cell line used in the lab was unexpectedly insensitive to 
LIF or IL-6 treatment; thus STAT3 signaling could not be activated in these cells. We 
therefore switched back to HEK293 cells that are highly LIF and IL-6 sensitive but kept the 
transient transfection approach. Cells were co-transfected with a STAT3-firefly luciferase 
construct and a control renilla luciferase construct employed for transfection efficiency 
normalisation. Cells were stimulated with 100 ng/ml of LIF 20 h post- transfection and 
incubated for 6 h. The results show that STAT3 activity was enhanced by EBNA2 in a 
concentration dependent manner (Fig. 2.16A) and that the EBNA2 point mutants reduced 
this effect (Fig. 2.16B). These results are in agreement with the results obtained with the 
stably transfected cells (Fig.2.14A and B). 
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Figure 2.16: Transient transfection of luciferase reporter construct together with EBNA2 and 
EBNA2 binding mutants. 2.5 x10
5
 HEK293 cells were transfected (using lipofectamine). (A) various 
concentrations of EBNA2 (100, 200, 300 and 400 ng) and 1 g reporter plasmid and control plasmid 
mix (40:1). (B) constant concentration (400 ng) of EBNA2 wt and point mutant constructs and 1 g 
reporter plasmid and control plasmid mix (40:1). Experiments were performed in triplicates. Luciferase 
signal was measured using the Promega dual luciferase reporter assay kit according to 
manufacturer’s instructions. 
 
 
We then confirmed that the general transactivation activity of EBNA2 was not impaired by 
the STAT3 interaction mutations. For this purpose, we measured the CBF1-EBNA2 
interaction via a well established CBF1 reporter assay (Hayward, 2004; Maier et al., 2005). 
The DG75 cells were transfected with a CBF1-firefly luciferase plasmid, a -galactosidase 
plasmid for transfection normalisation and a constant concentration of EBNA2 expression 
plasmid. The transactivation levels of both wild-type and mutant EBNA2 constructs were 
measured 2 days post electroporation. The results show that the general transactivation 
ability of EBNA2 was not impaired by the point mutations that disrupted STAT3 binding (Fig. 
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2.17). Only the EBNA2 deletion mutant CR8 was unable to activate CBF1 driven 
transcription. This was expected as this mutant lacked the whole conserved region 8 which is 
a large fragment of the transactivation domain of EBNA2. The EBNA2 mutant S448A 
seemed even to increase CBF1 mediated transcriptional activity, perhaps explained by the 
difference in expression level between EBNA2 wild-type and S448A (Fig. 2.15). 
 
Figure 2.17: CBF1 mediated transcription activation by EBNA2 wiltd-type amd STAT3 binding 
mutants. 5 x 10
6
 DG75 cells were transfected (using electroporation) with 1 g EBNA2 wild-type, 
point mutant construct or control vector, 5 g CBF1 reporter plasmid and 3 g -galactosidase. 
Experiments were performed in triplicates. Negative control: Luciferase vector with mutated CBF1 
binding site, Positive control: Luciferase vector with constantly active CMV promoter element. 
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2.1.11. Interaction of EBNA2 with other host cell proteins 
 
As side projects the interaction of EBNA2 with two partner proteins other than STAT3 were 
investigated and analyzed in regard of binding affinities and binding mutants. The BS69-
Mynd domain has been suggested to be involved in repression through N-CoR recruitment 
(Masselink and Bernards, 2000) and in cell growth control (Ansieau and Leutz, 2002). Med25 
is a subunit of the mediator complex which forms a bridge between transcription factors and 
the general transcription machinery (Borggrefe and Yue, 2011). 
2.1.11.1. Binding of EBNA2 to ZMYND 
EBNA2 was identified as a BS69 Mynd domain binding partner by yeast two hybrid screen of 
an EBV-immortalised B cell line using the BS69 Mynd domain as a bait. The screen 
identified the C-terminal part of EBNA2 as a binding partner. Sequence alignment with the 
adenoviral oncoprotein E1A, another already known binding partner of the BS69 Mynd 
domain, suggested two PXLXP (amino acids 383-387 and 437-441) motifs in EBNA2 to be 
the binding motifs. Pull-down experiments revealed that mutation of both motifs abrogates 
binding, whereas mutation of single motifs had no effect suggesting a redundancy of EBNA2 
PXLXP motifs (Ansieau and Leutz, 2002). Both PXLXP motifs identified in this study can be 
found in EBNA2 fragment D9. Wild-type and two PXLXP motif mutants (EBNA2 D9 L385A 
and EBNA2 D9 L439A) were subjected to SPR analysis. EBNA2 fragments were immobilised 
on a CM5 chip and Mynd domain protein was injected in a concentration range of 0.25 to 5 
nM. Binding curves of D9 wt to Mynd could be fitted using the BIAevaluation software and 
the 1:1 Langmuir binding model. The resulting KD is 450 nM (Chi value 0.25). The single 
PXLXP motif mutants did not show binding anymore (Fig. 2.18).  
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Figure 2.18: SPR sensograms of EBNA2 wild-type and PXLXP motif mutants binding to EBNA2 
fragment D9. A: Sensogram of EBNA2 fragment D9 binding to Mynd. Curves are fitted with a 1:1 
langmuirmodel. Concentration range of Mynd is 0.25 to 5 nM. B: Comparison of EBNA2 D9 wild-type, 
EBNA2 D9 L385A (mutant 1) and EBNA2 D9 L339A (mutant 2) binding to Mynd at a single 
concentration of 10 nM. 
 
The binding of the C-terminal domain of EBNA2 to Mynd domains was therefore confirmed 
together with the role of the PXLXP binding motif. Single PXLXP motif mutations abrogated 
binding in contrast to the pull-down experiments (Ansieau and Leutz, 2002, 69). 
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2.1.11.2. Binding of EBNA2 to Med25 
The Med25 activator interaction domain (ACID) has been shown to interact with the viral 
protein VP16 of herpes simplex virus I by NMR including a structural assignment (Vojnic et 
al., 2011). Due to structural and functional similarity between EBNA2 and VP16 and 
interaction of Med25 ACID and EBNA2 is presumably CR8. Med25 ACID protein was kindly 
provided by Alexis Verger (Université de Lille) and tested for EBNA2 binding by SPR. 
EBNA2 fragments F3, A11 and D9 were immobilised on a CM5 chip up to equal levels and 
Med25 was injected in the concentration range of 1-128 nM (Fig. 2.19). EBNA2 fragments 
A11 and D9 bound to Med25 ACID domain with the respective affinities of 2.63 nM for A11 
(Chi 0.56) and 4.52 nM for D9 (Chi 0.64). Values were obtained by global curve fitting using 
the two-state binding model. EBNA2 fragment F3 did not bind to Med25. Due to the overlap 
of A11 and D9 and the very similar binding affinities CR7 is suggested to be the binding 
region in EBNA2, however this project was not continued further so the significance or 
validity of these data awaits future confirmation. 
Figure 2.19: SPR sensogram of EBNA2 fragments binding to Med25 ACID and suggested 
binding site. A: Comparison of EBNA2 fragments F3, A11 and D9 binding to Med25 ACID at a single 
concentration of 128 nM. B: Sequence alignment of EBNA2 full length with the EBNA2 fragments 
suggest a possible binding region between amino acids 344 and 399 (black box) containing CR7. 
Light blue boxes indicate CRs. 
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2.2. Interaction of STAT3 with the cellular co-
repressor SMRT/NcoRII 
 
Under physiological conditions some of the cellular STAT3 is complexed by the nuclear co-
repressor SMRT (Ikeda et al., 2009). In transfection assays, it was demonstrated that this 
complex could be disrupted by EBNA2 (Muromoto et al., 2009a). In contrast to EBNA2 which 
activates STAT3 mediated transcription, binding of SMRT to STAT3 decreases its 
transcriptional activity. EBNA2 somehow releases SMRT from this complex (Ikeda et al., 
2009) with the probable, but not yet characterised, enhancement of transcription of both host 
and viral STAT3 regulated genes. STAT3 activity has several immunosuppressive effects in 
the host organism (Kortylewski et al., 2005b, 2009; Berg et al., 1996; Gerosa et al., 2008) 
and may therefore have importance in the viral survival strategy of Epstein-Barr virus 
(Koganti et al., 2013). Furthermore, EBNA2 interacts with STAT3 with significantly higher 
affinity and is therefore a further example of how viruses hijack the host cell immune system 
(Davey et al., 2011; Pushker et al., 2013). As a complement to the data on EBNA2-STAT3 
interactions, we performed similar studies on the interaction of SMRT and STAT3 with the 
aim of understanding both sides of this potentially antagonistic relationship. 
 
2.2.1. Identification of the binding region using a cell based 
approach 
 
The region of the 2525aa SMRT to which STAT3 binds is unknown so, in order to identify the 
binding site, an in vivo approach similar to that applied to EBNA2 was used. The SMRT gene 
was randomly divided into six fragments of equal size and expressed in HEK293-STAT3-Luc 
cells. This cell line was generated using lentiviral particles carrying the firefly luciferase gene 
under control of a specific STAT3 promoter. Cells were kept under puromycin selection 
pressure and isolated using the limiting dilution method to obtain stable, monoclonal cells. 
Interleukin-6, a well-known activator of STAT3 signalling was used to challenge cells after 
transfection with the SMRT fragment plasmids. The cell based assay shows a significant 
reduction in luciferase signal for fragments 3, 4 and 5 corresponding to a region spanning 
amino acids 820-1920 (Fig. 2.20). The next step was to further narrow down the binding 
region using recombinant protein and biophysical methods.  
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Figure 2.20: Luciferase signal induced by STAT3 stimulation with IL-6. 10
5
 cells/well of STAT3-
Luc HEK293 cells were plated into a 96-well plate in quintuplicates. After 24 h cells were transfected 
with pcDNA3-myc-SMRT1-6 (1-420, 421-820, 821-1260, 1261-1680, 1681-1920 and 1921-2525) and 
pCMV-SPORT--Gal. Cells were treated with 50 ng/ml of IL-6. After 12 h luciferase and -
galactosidase signals were detected.  
 
2.2.2. Expression and purification of SMRT fragment 
An ESPRIT expression library of random SMRT fragments covering amino acids 1089 to 
1993 of the SMRT protein had been already generated from which two purifiable constructs 
were isolated: 39L23 (aa 1256-1455) and 27M12 (aa 1785-1994) (D. Desravines and P. 
Mas, described in thesis of D. Desravines “Structural, functional and inhibition studies of 
human histone deacetylase 7”, 2010). 
The E.coli strain BL21 AI (RIL) was chosen for expression of these SMRT fragments and 
transformed by electroporation. Bacteria were grown in 1 l LB medium and protein 
expression was induced at an OD600 nm of 0.6 at 25
°C. Lysis was performed by 
microfluidisation. The soluble fraction was then incubated in a water bath with 95°C 
temperature for 10 min since a particular feature of the SMRT fragments studied was their 
extreme heat resistance, indicative of an absence of structure characteristic of IDPs. Lysate 
heating provided an efficient purification step since cellular proteins precipitated at these 
temperatures. The boiled lysate was cleared by centrifugation and remaining proteins further 
purified by affinity purificaton on NiNTA beads. After the first affinity purification, the fractions 
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with the highest purity were pooled and the 6xHis tag was cleaved with TEV protease. 
Proteins were diluted in wash buffer and incubated with NiNTA beads again to remove the 
cleaved 6xHis tag and the 6xHis tagged TEV protease. The efficiency of TEV cleavage was 
checked on SDS-PAGE (Fig. 2.21) and the proteins concentrated to the desired 
concentration. Using this protocol, a total purity of around 90% could be achieved with the 
total amount of protein per litre of bacterial culture approaching 10 mg. 
 
  
Figure 2.21: Expression of SMRT fragment 39L23. A: SMRT fragment 39L23 after 1
st
 affinity 
purification (FT: Flow through), W1 and W2: Wash 1 and 2, 1-9: Elution fractions 1-9, B: Size 
exclusion chromatography diagram for SMRT fragment 39L23. 
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2.2.3. Identification of a SMRT fragment binding to STAT3 
Two SMRT fragments, 39L23 (aa 1256-1455) and 27M12 (aa 1785-1994) were chosen and 
analysed by 1H15N HSQC NMR for STAT3 binding. Although the chosen fragments don’t 
cover the whole region identified in the cell based assay they still cover large parts of it (Fig. 
1). For this purpose the two SMRT fragments were 15N-labelled and spectra of the SMRT 
fragment in free form and in complex with various concentrations of STAT3 (3:1, 1:1, 1:3 and 
1:5) were recorded in collaboration with the Blackledge lab (IBS, Grenoble). One of these 
fragments, 39L23 shows binding to STAT3 indicated by peak intensity changes and shifts, 
whereas the other fragment, 27M12 does not bind to STAT3 (Fig. 2.22).  
 
 
Figure 2.22: NMR spectra of 39L23 (A) and 27M12 (B) upon titration of STAT3. The fragments 
were labelled with 
15
N and measured at a concentration of above 200 M in a volume of 250l. The 
ration between SMRT fragment and STAT3 is 1:1. Spectra recorded by R.Schneider (Blackledge lab, 
IBS Grenoble). 
2.2.4. Identification of the amino acids in fragment 39L23 
involved in STAT3 binding 
 
The 39L23 SMRT fragment was further investigated by NMR assignment (collaboration R. 
Schneider, Blackledge lab, IBS Grenoble). For this purpose the protein was expressed in 
minimal medium containing 15N-ammonium chloride and 13C-glucose. The assignment 
mapped each peak to the corresponding amino acid and allowed peak intensity change for 
each residue to be quantified upon addition of STAT3. The assignment showed that three 
regions within 39L23 are mainly affected by the binding: 79-89, 106-127 and 162-173 
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corresponding to residues 1336-1344, 1362-1383 and 1418-1429 in the full-length sequence 
(Fig. 2.23). 
 
 
Figure 2.23: Assignment of SMRT fragment 39L23. A: Peak intensity changes upon STAT3 titration 
from 1- to 5-fold access. B: Amino acids involved in STAT3 binding. Each bar of the histogram 
corresponds to one residue of fragment 39L23. C: Location of the STAT3 binding region within 39L23 
from the NMR data. Assignment performed by R. Schneider (Blackledge lab, IBS Grenoble). 
2.2.5. Binding kinetics and mutational analysis of the 
STAT3-39L23 binding 
 
Deletion mutants were generated for the regions showing the highest peak intensity changes 
(Fig 2.23c): Δ79-89, Δ106-127 and Δ162-173 as well as one longer deletion mutant Δ79-127. 
The mutants and wild-type 39L23 were tested for binding to STAT3 by SPR (Fig. 2.24). 
There were no significant differences between the single deletion mutants and the wild-type 
detectable. Only the mutant lacking both region 1 and 2 showed a significant change in 
binding mode and binding affinity.  
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Figure 2.24: Sensograms and fitted curves of immobilised 39L23 wild-type (A) and  1+2 (B) 
binding to STAT3 injected from 125 nM to 1 M in low salt buffer conditions (10mM MgCl2). Data 
recorded together with M. Roth (Trainee, Hart team, EMBL Grenoble). 
 
The wild-type 39L23 fragment bound to STAT3 resulting in sensograms best fitted to a two-
step model with fast and slow association/dissociation which has been used to describe IDP 
interactions by SPR previously (Sevcik et al., 2007a). Using this model, the data could be 
fitted with high confidence (chi2 2.947) to give a KD of 121 nM (Fig. 2.24A. The higher 
response values of mutant Δ79-127 indicated a significantly higher level of binding, but could 
no longer be fitted by the two-state model. Instead, the data was better described by the 
most simple 1:1 one-state model predicting an increased affinity of 19 nM (Fig. 2.24B).   
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Discussion and Outlook 
Résumé 
Interactions entre EBNA2 et STAT3  
Le transactivateur viral EBNA2 a été décrit a maintes reprises dans la littérature a propos de 
sa fonction, cependant sa structure est faiblement caractérisée. EBNA2 interagit avec 
beaucoup de virus ainsi que des protéines cellulaires de l’hôte. Beaucoup d’interacteurs ont 
été identifies, néanmoins sa caractérisation biophysique et ses propriétés tant biochimiques 
que structurelles sont piètrement mise en évidence. Surtout, les interactions d’EBNA2 liées à 
ses particularités intrinsèquement désordonnées restent un mystère. L’interaction avec 
STAT3 fut étudiée en détail de manière a comprendre l’un des nombreux aspects de la 
stratégie de survie de l’EBV, a savoir l’efficace échappatoire au système immunitaire de la 
cellule hôte et du contournement de la régulation cellulaire. Les résultats qui incluent la 
création d’une banque de constructions aléatoire (ESPRIT) d’EBNA2, l’expression et la 
purification de fragments d’EBNA2 ainsi que le dimère de STAT3; montrent la cinétique 
d’interaction ainsi que les sites impliques a travers celle ci. Il sera également discuté d’autres 
expériences à réaliser qui impliquent principalement de la culture cellulaire. 
Interactions entre EBNA2 et d’autres protéines hôte          
EBNA2 a été extensivement étudie et il est clair que ce dernier est impliqué de façon 
fonctionnelle dans beaucoup de processus cellulaires. A travers une étude de double hybride 
a haut débit, il a été découvert que cette protéine interagit avec 16 autres partenaires 
cellulaires. L’interaction d’EBNA2 avec BS69 Mynd et Med25 fut étudie préalablement. Ici, 
ces interactions furent confirmées par SPR et des sites de fixation suggérés. 
Interactions entre SMRT et STAT3   
Trois régions de SMRT (1336-1344, 1362-1383 and 1418-1429) eurent un effet sur 
l’interaction de STAT3. D’une façon surprenante, aucune des délétions générées par 
mutation n’ont affecte individuellement de façon significative l’interaction. Cependant, la 
délétion de deux régions de fixation (aa 80-127) a drastiquement modifié le mode de fixation. 
Ce dernier fut modifié d’un simple 1:1 mécanisme de Langmuir et l’affinité de fixation fut 
augmentée d’environ 10 fois a 19 nM. Les possible explications de cette observation 
inhabituelle pourrait être que la région de fixation 3 (non abolie) est initialement auto inhibée 
par les régions 1 et 2, peut être masquant un motif d’interaction a STAT3. La délétion des 
régions 1 et 2 pourrait mener à des interactions plus fortes à STAT3. Alternativement, SMRT 
est constitué par une grande organisation de type “échafaudage” qui serait engagé avec 
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STAT3 à travers des régions additionnelles en dehors du fragment 39L23. Ces résultats 
furent mis en évidence par des expériences de “cell based assay” ou des fragments de 
SMRT (AA821 a 1920) ont diminué la transcription régulée par STAT3. L’hypothèse est que 
SMRT supprime l’activité de transcription de STAT3 par un recrutement d’autres protéines 
telles que HDACs qui inhibe activement la transcription.    
Protéines intrinsèquement désordonnées (IDPs) 
EBNA2 et SMRT sont prédites comme étant des protéines intrinsèquement désordonnées. 
Des études structurales de cette protéine sont peu abondante en comparaison des protéines 
ayant un repliement, même si la majorité des oncoprotéines et la moitie des autres protéines 
cellulaires sont prédites comme étant des IDPs. Ces dernières sont localement structurées 
après leur fixation à des protéines partenaires, parfois a travers des motifs linéaires ou de 
courtes hélices alpha, mais aussi a travers des événements plus prononcés de repliement 
après interaction. A ce moment, des liaisons électrostatiques faibles sont suivies par un 
changement conformationnel sont le résultat d’une seconde interaction plus spécifique ainsi 
qu’une plus grande affinité. Ce mécanisme a été décrit comme “fly casting” et complète le 
dogme longtemps établi du système clé serrure qui correspond a la relation structure 
fonction. Des défis spécifiques existent avec les IDPs, surtout la sensibilité aux protéases et 
la difficulté de concevoir des constructions pour de l’expression. Ces deux difficultés ont été 
résolues en utilisant ESPRIT. Néanmoins après isolement, ces protéines se sont comportées 
de façon remarquable quant a leur facilite de manipulation due a leur absence de structure à 
dénaturer. Plusieurs idées ont été avancées à propos de l’avantage biologique de ces IDPs 
et sont discute ici. En raison de leur rôle clé dans beaucoup de procèdes cellulaires et de 
maladies mais aussi du fait de leur abondance dans le protéome, les IDPs sont des cibles 
très intéressante en Recherche. 
La triade d’interaction: EBNA2 en compétition avec SMRT pour l’interaction de STAT3 
Dans des conditions physiologiques, le corépresseur SMRT se fixe a beaucoup d’adapteurs 
et de facteurs de transcriptions (par exemple, STAT3) et concilie la suppression de la 
transcription a travers le recrutement d’autres protéines de répression tells que les HDACs 
qui causent une deacetylation des gènes cibles afin d’inhiber leur transcription. Lors de 
l’infection de l’EBV d’une cellule, EBNA2 relargue SMRT du complexe. Ceci permettrait 
d’activer la transcription régulée de STAT3 qui se produit sensiblement par recrutement 
d’enzymes d’activation telle que la machine de transcription basale. STAT3 active est pro 
prolifératif, anti apoptotique et montre plusieurs activités suppressive sur l’immunité. De plus, 
des études sur HSV montrent l’hypothèse que STAT3 est requis pour maintenir la latence. 
Dans une autre étude, il est décrit qu’EBNA2 régule l’activation de STAT3 qui serait 
responsable de la prolifération et de l’oncogenèse. Aussi, une aberrante activation de STAT3 
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est retrouvée dans d’autres virus herpétiques. Ceci renforce la preuve que STAT3 est un 
facteur déterminant de la prolifération cellulaire et la survie des cellules B infectée par l’EBV. 
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3.1. The interaction between the viral protein EBNA2 
and STAT3 
 
The viral transactivator EBNA2 interacts with many viral and host cell proteins (Calderwood 
et al., 2007). Although many interactors have been identified, there exists little 
characterisation beyond this with respect to their biophysical, biochemical and structural 
properties. Notably the characterisation of EBNA2 interactions from the perspective of its 
disorder properties remains almost unstudied. One explanation for this lack of study might be 
that EBNA2, as an IDP, cannot be expressed full length in high yielding recombinant 
systems (at least we can find no reports of this in the literature). The predicted absence of 
three-dimensional domains means that the generation of expression constructs via the 
classical domain-focused design approach is not really possible. To address this, we present 
a new approach for obtaining fragments of a size and yield suitable for biophysical studies. 
The generation of a random expression library (ESPRIT) proved to be an effective and time-
saving alternative to the classical PCR approach yielding multiple constructs that expressed 
milligrams of purifiable proteins in just a few weeks. The library efficiency was good with 
most of the 96 positive clones giving some level of detectable protein by SDS-PAGE. From 
these, three were chosen according to their location and expression level. The obtained 
EBNA2 fragments named F3 (aa 161-296), A11 (aa 294-399) and D9 (aa 344-475) were 
well-behaving and yielded up to 10 mg per litre of bacterial culture. Biochemical and 
biophysical analyses of these fragments showed that they were intrinsically disordered as 
evidenced by unusual thermal stability, sensitivity to protease digest, retarded running 
behavior in SDS-PAGE, accelerated elution in size exclusion chromatography and narrow 
peak distribution in HSQC NMR spectra.  
The EBNA2 constructs show promise for studying interactions as evidenced by preliminary 
results with Mynd and Med25, and in more detail with STAT3. The interaction with STAT3 
was studied in detail in order to understand an important aspect of the EBV survival strategy 
namely the effective escape from the host cell immune system and circumvention of cell 
regulation mechanisms (e.g. pro-proliferative and anti-apoptotic effects). 
The interaction between EBNA2 and STAT3 was initially shown by pull-down experiments 
and luciferase assays in 2009 (Muromoto et al., 2009a); here we have validated this further 
using a number of biophysical and biochemical assays. The interacting EBNA2 fragment D9 
was identified as the major STAT3 interacting region by streptavidin pull-down experiments 
(Fig. 2.6B) and SPR (Fig. 2.6A). The EBNA2 fragment F3 also interacted with STAT3 but 
with much lower affinity (Fig. 2.7). Therefore it was decided that the major binding region 
must lie within EBNA2 fragment D9, perhaps complemented by a weaker upstream motif in 
F3. 
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Further characterisation by NMR (Fig. 2.8) revealed the interaction was mediated by a limited 
number of interacting residues only i.e. seemed to be specific. The NMR spectrum in 
combination with the knowledge of the CRs within EBNA2 (Fig. 2.9) indicated that the 
binding region covered CR8, one out of 9 CRs within EBNA2, and which is located close to 
the C terminus. CRs in proteins are often indicative of functional importance. In folded 
domains, the sequence may have structural importance, but in IDPs it is perhaps indicative 
of linear interaction motifs. CR8 is located between aa 437-449 and therefore lies right in the 
middle of the acidic transactivation domain (TAD) that is located between amino acids 426 
and 483 (Tong et al., 1995).  
The critical amino acids for the interaction with STAT3 were determined via site directed 
mutagenesis and SPR, further validating that binding was specific. These mutations were 
also tested in cellular assays to see if the same effects could be measured under more 
physiological conditions. Initial results indicate that this is the case and that inhibition of 
STAT3 binding does not affect the overall transactivation function of this region. Further work 
is underway in collaboration with the Kempkes lab in Munich and will involve the following 
experiments: 
1. The STAT3-luciferase assay was performed repeatedly with transient and stably 
transfected cells and resulted each time in a decrease in STAT3 mediated 
transcription activation for the mutants compared with wild-type EBNA2. However, the 
mutants tested did not completely inhibit, so it remains necessary to repeat the work 
to get better statistical parameters.  
2. Also, our collaborators will repeat the CBF1 reporter assay, or perform a Gal4 
transactivation assay, which monitors the general transactivation ability of EBNA2. In 
this assay EBNA2 will be fused to the Gal4 DNA binding domain and the 
transactivation levels of both wild-type and mutant EBNA2 constructs will be 
measured by luciferase assay. This is significant because one of the mutated amino 
acids within our triple mutant constructs (Trp 454) was identified previously as crucial 
for transactivation and subsequent transformation of B cells (Cohen, 1992). 
Surprisingly, neither of these mutant EBNA2 forms affected activation of CBF1-
mediated transcription suggesting that the normal transactivation function was 
unaffected (Fig. 2.17). 
3. The differences in EBNA2 function between wild-type and point mutants could be 
studied with a recent approach based (Kempkes et al., 1995; Lucchesi et al., 2008) 
on EBV infected cells that lack the EBNA2 gene locus and which are engineered to 
express EBNA2 fused to the hormone-binding domain of the oestrogen receptor. 
These cells are maintained in growth medium supplemented with oestrogen 
whereupon EBNA2 is imported in the nucleus. Upon removal of oestrogen, EBNA2 
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becomes localised in the cytoplasm and cells undergo apoptosis due to the abolished 
EBNA2 activity. By transient expression of unfused EBNA2 the cells can be rescued. 
Thus the system can be used to study the function of EBNA2 mutants. Furthermore, 
in order to identify host genes that are affected by the EBNA2-STAT3 interaction, RT-
PCR and western blot analyses could be used as a read-out in this system. Based 
upon our preliminary data, we would expect that EBNA2 point mutants would affect 
the expression of a number of STAT3-dependent host genes that could then be 
compared to those identified via chromatin precipitation studies (Snyder et al., 2008; 
Vallania et al., 2009). 
4. Beyond this cellular assay format, a recombinant EBV containing EBNA2 point 
mutations that prevent the STAT3 interaction could be generated and tested in B 
cells. Infected cells could then be analysed regarding their infection rate, 
transformation efficiency, viability of the cells and spontaneous lytic reactivation. Our 
hypothesis is that viruses with wild-type EBNA2 will infect and transform cells more 
efficiently than mutants that precisely disrupt STAT3 binding.  
 
Collectively these experiments seek to show how EBV uses EBNA2 to subvert STAT3 
signalling, and by comparison with interaction mutants, will reveal the effects of this host-
virus interaction on cellular and viral functions.  
The biophysical and biochemical results presented would ideally be complemented with a 
crystal structure of STAT3 in complex with an EBNA2 binding peptide. Different short EBNA2 
binding constructs fused to a GST tag were analyzed for STAT3 binding. One 32 aa peptide 
was identified as the minimal binding region and synthesised chemically. This was added to 
the STAT3-DNA complex and small crystals were obtained in around 70 conditions. Six data 
sets were collected at the SOLEIL synchrotron (Proxima I beamline), but diffracted only to 
6.5 Å resolution and it was not clear if the peptide co-crystallised. An intensive effort is now 
required to obtain bigger and better diffracting crystals. 
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3.2. The interaction between EBNA2 and other host 
proteins 
 
EBNA2 has been well studied (~900 papers in PubMed) and it is clear that it is functionally 
involved in many cellular processes. In one high-throughput yeast two-hybrid study it was 
found to bind sixteen different cellular partners (Calderwood et al., 2007). The interaction of 
EBNA2 with BS69 Mynd and Med25 was previously studied (Ansieau and Leutz, 2002; 
Milbradt et al., 2011, 25; Vojnic et al., 2011, 25), but the availability of highly purified EBNA2 
fragments permitted further quantitative analyses to be performed.  
3.2.1. Interaction between EBNA2 and the BS69 MYND 
domain 
 
A yeast two-hybrid screen of an EBV-immortalised B cell line using the BS69 Mynd domain 
as bait identified the C-terminal part of EBNA2 as a binding partner (Ansieau and Leutz, 
2002, 69). Sequence alignment and comparison with the adenoviral oncoprotein E1A, 
another known binding partner of the BS69 Mynd domain, suggested two binding motifs in 
EBNA2: PXLXP (aa 383-387 and 437-441). Pull-down experiments revealed that mutation of 
both motifs in EBNA2 abrogated binding, whereas mutation of single motifs had no effect 
suggesting a redundancy of EBNA2 PXLXP motifs (Ansieau and Leutz, 2002). EBNA2 
fragment D9 also contains both motifs. Single and double mutations were introduced (L385A 
and L439A) and subjected to binding analysis via SPR. The published hypothesis for E1A, 
suggesting a redundancy of the motif, could be not confirmed for EBNA2 where a single 
mutation of just one of the PXLXP motifs abolished binding completely (Fig. 2.18). However, 
the previously published data were based on pull-down experiments in which the BS69 
(411–561) Mynd domain was expressed as a GST-fusion protein together with single and 
double mutants of EBNA2 (L385A and L439A). Pull-down experiments can yield false 
positive signals due to unspecific binding to the beads and from the data in the publication it 
is not clear whether this was the case. Another reason might be that the protein lysates used 
for pull-down experiments contain many different proteins and binding of the single mutants 
of EBNA2 to BS69 Mynd could have been facilitated by additional unknown binding partners. 
In contrast, SPR experiments are more specific since they use highly purified proteins, but it 
is also a highly artificial system that only permits evaluation of the interaction between ligand 
and analyte.  
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3.2.2. Interaction between EBNA2 and Med25 
The structure of the Med25 acidic domain was solved by NMR (Bontems et al., 2011). In 
2011 the solution structures of the Med25 VP16 binding domain (Med25 VBD) and the VP16 
transactivation domain (VP16 TAD) (Milbradt et al., 2011) were published and the structural 
and functional interaction between these two proteins was detailed (Vojnic et al., 2011). 
Structural sequence alignment of VP16 and EBNA2 suggested that the binding site in 
EBNA2 is located between aa 435-452 covering CR8. Binding analyses of EBNA2 fragments 
F3, A11 and D9 with Med25 revealed that fragment A11 and D9 interact with Med25 with 
similar affinities (2.63 nM for A11 and 4.52 nM for D9). This suggests that the binding region 
is located within the overlap of both fragments which contains just one conserved region, 
CR7. Thus CR7 may be the binding site in EBNA2 for Med25 or, alternatively, EBNA2 may 
contain at least two binding sites for Med25. One of them might be within CR8 as suggested 
by sequence alignment whilst the other one is located within the N-terminal part of fragment 
A11 that contains CR5 and 6. Deletion mutants for CR5, 6, 7 and 8, assayed for interaction 
with Med25, would confirm which hypothesis is the right one. 
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3.3. The interaction between the cellular protein SMRT 
and STAT3 
 
SMRT is significantly bigger than EBNA2, so in order to narrow down the STAT3 binding 
region within the 2525 aa long protein 6 SMRT fragments were expressed in stable STAT3-
Luc reporter cells and the effects were assessed by luciferase signal (Fig. 2.20). The SMRT 
fragments showing a decrease in STAT3 mediated transcription activation were found within 
the region aa 820-1920. Two recombinant SMRT fragments covering most of this region, 
39L23 (aa 1256-1455) and 27M12 (aa 1785-1994) were selected from a previous ESPRIT 
screen and analysed by HSQC NMR for evidence of STAT3 binding (Fig. 2.22). Fragment 
39L23 bound STAT3 and the SMRT amino acids involved were identified following 
assignment of the peaks (Fig. 2.23). Three individual regions exhibited changes upon STAT3 
binding; these were located between aa 80-88, 106-127 and 162-173, corresponding to 
SMRT residues (1336-1344, 1362-1383 and 1418-1429). Three deletion mutants were then 
constructed and tested separately for STAT3 binding using SPR. Surprisingly, none of the 
deletion mutations individually affected the binding significantly. In contrast, the deletion of 
two binding regions (aa 80-127) significantly changed the binding behavior (Fig. 2.24). The 
two-state binding mechanism of STAT3-SMRT (1256-1455) that has been reported 
previously to describe IDP interactions (Sevcik et al., 2007b), with both fast and slow 
association and dissociation steps, changed to a simple 1:1 Langmuir binding mechanism 
and the binding affinity increased nearly 10-fold to 19 nM (Fig. 2.24). Possible explanations 
for this unusual observation may be that a binding site in region 3 (not deleted) is initially 
autoinhibited by regions 1 and 2, perhaps masking a STAT3 interaction motif. Deletion of 
regions 1 and 2 may lead to a tighter interaction with STAT3. Alternatively, SMRT as a large 
scaffold protein may bind STAT3 via additional regions outside fragment 39L23, in possible 
agreement with the results from the cell based assay where SMRT fragments corresponding 
to aa 821 to 1920 decreased STAT3 mediated transcription (Fig. 2. 20). Compared to 39L23 
which covers aa 1256-1455 this is a significantly bigger region. Further work will be 
necessary to test these ideas. 
 
The STAT3 residues involved in SMRT binding are not known, however other observations 
may hint at two possible binding sites on STAT3. SMRT was reported to bind the coiled-coil 
domain of STAT5 (Nakajima et al., 2001) while other groups reported a binding of a YXXQ 
motif to the SH2 domain of STAT3 (Shao et al., 2004). The second hypothesis was tested by 
adding SMRT (1256-1455) at saturating concentrations to a STAT3-DNA gel-shift assay 
since this motif is present in 39L23, however results were inconclusive (data not shown). No 
release of STAT3 from DNA was observed suggesting SMRT did not compete with DNA 
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binding under the conditions tested. An alternative and perhaps stronger hypothesis is that 
SMRT binds to the coiled-coil domain of STAT3 (as shown for STAT5) and suppresses 
STAT3 transcriptional activity through recruitment of other proteins e.g. HDACs that actively 
inhibit transcription. 
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3.4. Intrinsically disordered proteins 
Both the cellular co-repressor SMRT and the viral trans-activator EBNA2 are predicted to be 
highly intrinsically disordered. Structural studies of this protein type are relatively rare when 
compared to folded proteins, even though the majority of oncoproteins and half of all cellular 
proteins are predicted IDPs. Also, certain viruses are characterised by a high amount of 
disorder within their proteomes. Herpes viruses were found to possess 17,9% of disorder 
(Pushker et al., 2013). The determination of the structure of something unstructured might 
look illogical at the first glance, but IDPs become locally structured upon binding partner 
proteins, often via linear motifs or short α-helices, but sometimes via more pronounced 
folding-upon-binding events (Dyson and Wright, 2005b; Tompa, 2005; Sugase et al., 2007b). 
Specific challenges exist when working on IDPs, notably protease sensitivity and the 
difficulty in designing meaningful expression constructs; both of these have been addressed 
by the use of ESPRIT. However, once obtained, such proteins can be surprisingly easy to 
handle since they have no structure to denature. One demonstration of this is extreme heat 
resistance that was exploited in this work as an enrichment step after E. coli cell lysis, prior to 
affinity purification. 
Some insights into how EBNA2 binds STAT3 may be obtained from the transactivation 
domain (TAD) of the herpes simplex protein VP16, which shares functional and structural 
features with EBNA2 (Ansieau and Leutz, 2002, 16). This was shown to undergo 
conformational changes from random coil to significant -helical content when binding 
partner proteins (Jonker et al., 2004; Uesugi et al., 1997). It was furthermore shown that the 
first interaction between VP16 TAD and binding partner was electrostatically driven and 
induced structural changes around hydrophobic residues important for the adoption of an -
helical conformation. In this work, EBNA2 and SMRT binding to STAT3 were studied by SPR 
in order to gain kinetic and mechanistic insights. Previous analyses of IDP interactions by 
SPR, such as the binding of a monoclonal antibody to the IDP Tau (Sevcik et al., 2007b), 
suggest a two-step mechanism can be used for fitting data (see chapter 2.1.3.1 and 2.2.5). 
This model best described the experimental data and is in line with a first weak electrostatic 
interaction followed by conformational change resulting in a second higher affinity specific 
binding event. This mechanism has been termed “fly-casting” (Shoemaker et al., 2000a) and 
complements the long established “lock and key” hypothesis relating structure with function. 
Several ideas have been proposed regarding biological advantages of IDPs: first, cell cycle 
regulation may require a fast turnover of proteins which is facilitated by the fact that IDPs are 
more sensitive to proteolytic degradation (Kriwacki et al., 1996) (see chapter 2.3.2). Second, 
the increased interaction area of IDPs may allow an easier capture of binding partners 
(Shoemaker et al., 2000b) and also an increased interaction speed when folding-upon-
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binding, rather than prior to binding, was suggested as it leads to a significant reduction of 
the free-energy barrier (Huang and Liu, 2009). It has been also suggested that IDPs confer 
stability to complex regulatory networks as they are less sensitive to environmental changes 
e.g. temperature increase (Lee et al., 2001). Post-translational modification and alternative 
splicing sites are very often located within disordered regions conferring a high variability and 
adaptability upon a single primary sequence (Dunker et al., 2008). This variability as well as 
the possibility to fold-upon-binding allows many specific interactions to be made with multiple 
partners, perhaps explaining the apparent promiscuity of many IDPs.  
Both SMRT and EBNA2, are known to undergo interactions with many binding partners. 
SMRT is a huge hub-protein with a length of 2525 amino acids and so the high number of 
interaction partners described (Dhordain et al., 1998b; Li et al., 2000b; Nakajima et al., 
2001b; Jepsen and Rosenfeld, 2002b) is to be expected. But EBNA2, at 487 aa, is quite 
small for its number of interaction partners (Tong et al., 1995; Ansieau and Leutz, 2002, 69; 
Kwiatkowski et al., 2004; Calderwood et al., 2007; Muromoto et al., 2009b) and perhaps this 
can now be explained by its lack of order and high flexibility. 
Knowledge of the structure of the binding interface between an IDP and its partner may 
ultimately lead to the development of new anti-cancer drugs that act by inhibiting complex 
formation. Because of their key roles in many cell processes and in many diseases, as well 
as their abundance in the proteome, IDPs are clearly interesting research targets. The study 
of IDPs only began around 15-years ago but it is becoming a very active area. Bioinformatics 
has played a key role in identifying IDPs, and high throughput studies in cataloging their 
interactions; now more effort should be made to validate these interactions and their 
mechanisms. In addition to investigating EBV biology, the work presented here has sought to 
address the areas of sample production and analysis in a manner that should be applicable 
to IDPs more generally.  
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3.5. The interaction triad: EBNA2 competing with 
SMRT for STAT3 binding 
 
Under physiological conditions the co-repressor SMRT binds to many adaptors and 
transcription factors (e.g. STAT3) and mediates transcriptional suppression via recruitment of 
other repressing proteins such as HDACs that cause deacetylation of target genes in order 
to inhibit their transcription (Battaglia et al., 2010). Upon EBV infection of the cell, EBNA2 
was shown to release SMRT from the complex (Muromoto et al., 2009a). This might be 
expected to activate STAT3 mediated transcription and happens presumably though 
recruitment of activating enzymes e.g. the basal transcription machinery (Tong et al., 1995) 
(Fig. 3.1), although currently no studies have shown this. Activated STAT3 signaling is pro-
proliferative (Zushi et al., 1998; Bromberg et al., 1999; Rahaman et al., 2002), anti-apoptotic 
(Zushi et al., 1998; Shen et al., 2001; Aoki et al., 2003; Bhattacharya et al., 2005) and has 
several immune suppressive effects (Kortylewski et al., 2005a, 2009; Berg et al., 1996; 
Gerosa et al., 2008) (see 1.2.2 for details). Furthermore, it was hypothesised for HSV that 
STAT3 is required for the maintenance of the latent state as interference with STAT3 
functions leads to reactivation of the latent virus in ganglia (Du et al., 2013). Because of the 
close similarity of both viruses this might be transferable to EBV. It was found recently that B 
cells containing a dominant negative mutation of STAT3 are resistance to EBV induced cell 
outgrowth (Koganti et al., 2013). It was therefore hypothesised that EBNA2 mediated STAT3 
activation is highly connected with oncogenesis. Abberant STAT3 activation could be also 
found in other herpes viruses e.g. HCMV (Reitsma et al., 2013), KSHV (King, 2013) and 
Herpesvirus saimiri (Chung et al., 2004). This reinforces the evidence that STAT3 is a crucial 
factor for cell proliferation and survival of EBV infected B cells.  
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Figure 3.1: Proposed mechanism of STAT3 activation by EBNA2. A: SMRT binds to STAT3 and 
suppresses its transcriptional activity via recruitment of other repressing proteins. B: Upon EBV 
infection of the cell, EBNA2 releases SMRT from the complex and causes STAT3 mediated 
transcription activation though recruitment of activating. 
 
A model is hereby proposed (Fig. 3.1) that takes into account the measurements made 
during this work. EBNA2 and SMRT compete for binding to STAT3 and EBNA2 is able to 
displace SMRT through a higher affinity for STAT3. The KD values as measured by SPR are 
7 nM for EBNA2 (Fig. 2.7) compared with 120 nM for SMRT (Fig. 2.24). This is in agreement 
with the observation that many viruses use short non-globular interaction interfaces that are 
adapted from host protein binding interfaces but which exhibit a higher affinity for the partner 
protein (Davey et al., 2011). In the context of IDPs, host linear motifs that bind with a medium 
affinity necessary for their function can be mimicked easily by viruses with adaptation of the 
sequence for high affinity.  
The EBNA2-SMRT-STAT3 triad represents only one aspect of how EBV hijacks the host cell 
processes and establishes a lifelong alliance with the host cell. Many other processes clearly 
occur, but are beyond the scope of this work that focuses on interactions of recombinant 
purified proteins. In addition to the proposed cell based work which aims to study the 
biological significance of the binding it would be interesting to study and compare the 
dynamics of the viral and physiological interaction. A new tool to study protein dynamics is 
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in-cell NMR (Selenko and Wagner, 2007; Serber et al., 2007; Binolfi et al., 2012; Tochio, 
2012). It permits the study of protein dynamics at atomic resolution in living cells. In order to 
record a protein spectrum inside a cell the protein of interest needs to be selectively isotope-
labelled and highly overexpressed if E. coli is the host, or microinjected into mammalian cells 
which might have negative effects on biological function (Li and Liu, 2013) but the technique 
is still in its infancy and improvements are ongoing. Nevertheless, the in vitro methods used 
here may soon be complemented by more in vivo type measurements in the crowded milieu 
of the cellular cytoplasm/nucleoplasm. 
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Material and Methods 
4.1. ESPRIT technology 
The synthetic gene sequence of EBNA2 from EBV strain B95-8 (encoding a protein identical 
to UniProt P12978 EBNA2_EBVB9) was purchased from Geneart with codon optimisation for 
E. coli expression. This process recodes the gene sequence to employ codons preferred by 
E. coli, eliminates internal ribosome binding sites and reduces mRNA secondary structure.  
The expression vector pESPRIT002 contains a N-terminal 6xHis tag followed by a TEV 
protease cleavage site (MGHHHHHHDYDIPTTENLYFQG) and a C-terminal biotin acceptor 
peptide with linker (SNNGSGGGLNDIFEAQKIEWHE). In order to direct the exonuclease III 
digest the gene within pESPRIT002 is flanked by two restriction sites on each end of the 
gene. AatII/AscI are located on the 5' end of the gene and NsiI/NotI are on the 3' end. 
 
Figure 4.1: Vector map pESPRIT002 backbone vector. Restriction sites used in ESPRIT library 
synthesis are shown. The vector is derived from pET9a. 
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4.1.1. ESPRIT- experimental procedure 
 
Manipulation of DNA 
Mach1 E. coli cells (Invitrogen) were chemically transformed with pESPRIT002 containing 
the EBNA2 gene and DNA was isolated from 200 ml overnight culture by alkaline lysis and 
phenol chloroform extraction and ammonium acetate precipitation. The plasmid was further 
purified with a DNA miniprep kit (Qiagen) in order to remove residual RNA and salts. Ten 
micrograms of plasmid were digested with AatII and AscI for 5’ truncation, and NotI and NsiI 
for 3‘ truncation for 4 h in 200 µl reactions. Four micrograms of linearised plasmid were used 
for the truncation with 400 U of exonuclease III (NEB) at 22 °C in 120 µl total volume. The 
kinetics of the truncation reaction were adjusted to the EBNA2 DNA size by addition of 50 
mM NaCl. Two microlitre of the digestion mixture were removed every 60 s and quenched 
into a single tube containing 200 µl of 3 M NaCl. After 60 min the exonuclease was heat 
inactivated at 70°C for 20 min. DNA was purified with a Nucleospin Extract kit (Macherey 
Nagel) and eluted in 35 µl of elution buffer. The single stranded DNA extension was removed 
with Mung Bean nuclease (NEB) (5 U enzyme, 30°C, 30 min) and Pfu polymerase 
(Stratagene) (72 °C, 20 min, 25 mM dNTPs). The unidirectionally truncated DNA was 
electrophoresed at 5 V/cm on an ethidium bromide-containing 0.5% w/v agarose gel at 4°C. 
The smear visible on the gel was cut and gel purified with Nucleospin Extraction kit 
(Macherey Nagel) and purified DNA recircularised by ligation with a Rapid Ligation kit 
(Roche) and recovered by transformation of Mach1 cells. All colonies were recovered as a 
single pellet from LB agar plates and plasmid DNA extracted. The protocol was repeated to 
truncate the 3’ end of the gene. This time fractions of 0-500 bp, 500-1000 bp and 1000-1500 
bp were isolated from the agarose gel (Fig. A.1) and DNA extracted, recircularised by ligation 
Mach1 cells transformed. Approximately 30,000 colonies were pooled from LB agar plates 
and plasmids containing randomly bidirectionally truncated EBNA2 inserts were extracted 
using a midiprep kit (Qiagen) and used to transform electrocompetent BL-21 AI (DE3) RIL 
cells (Invitrogen).  
Screening of the generated diversity of library clones 
Transformed cells were spread on Qtrays (Genetix) containing 300 ml LB agar 
supplemented with kanamycin (50 µg/ml) and chloramphenicol (50 µg/ml). A picker-gridder 
robot (KBiosystems) isolated around 28000 clones into 384 well plates (Genetix) containing 
80 µl of TB with 10% final glycerol. Cultures were grown overnight at 37 °C in a HiGro 
incubator (GeneMachines) and frozen. Freshly replicated copies of these plates were 
robotically arrayed onto a nitrocellulose membrane (Amersham) laid on a Qtray containing 
300 ml LB agar with antibiotics. Colonies were grown overnight at room temperature and the 
nitrocellulose membrane was transferred to a fresh Qtray containing LB agar, antibiotics, 50 
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µM biotin and 0.2% L-arabinose. Protein induction was performed for 4 h at 30 °C. The 
membrane was transferred onto filter paper soaked with denaturing solution (500 mM NaOH, 
1.5 M NaCl) for 10 min to lyse the colonies and then neutralised with neutralisation solution 
pH7.5 (1M Tris HCl, 1.5 M NaCl) twice for 5 min. Finally, the nitrocellulose array was 
incubated in 2× SSC solution pH7 (300 mM NaCl, 35 mM Na Citrate) for 15 min to remove 
cell debris. The activated membrane was placed in a roller incubator (Techne) and unspecific 
binding sites blocked overnight with 50 ml of SuperBlock (Pierce). Then the membrane was 
incubated with mouse anti-his-tag antibody (dilution 1/3125, Amersham) in 0.1% Tween-PBS 
for 1 h at 4 °C. The membrane was washed 3 x 5 min with 0.1% Tween-PBS. Streptavidin 
labelled with Alexa488 (dilution 1/5000, Molecular probes) and secondary antibody anti-
mouse Alexa532 (dilution 1/1000) were incubated with the membrane for 45 min at 4 °C. 
Three final washing cycles with 0.1% Tween-PBS and one washing cycle with water 
followed. The membrane was scanned using a Typhoon imager (GE Healthcare) and 
analysed using VisualGrid software (GPC Biotech). Data were transferred to MS Excel for 
analysis and clones exhibiting strong signals for both histidine and biotin tags identified. 
Selection of the best protein clones 
The 96 best clones were transferred into a 96 deep-well plate (Qiagen) and grown overnight 
in the HiGro plate shaker (37 °C at 220 rpm). Protein expression trials were performed in 4 
ml TB medium in 24 deep-well plates (Qiagen). Cultures were grown at 37 °C and induced at 
OD 600 0.6-0.8 with 0.2% arabinose for 16 h at 25 °C. Cells were harvested by 
centrifugation at 3700 rpm for 10 min in a swinging rotor and the cell pellets resuspended 
with 4 ml of resuspension buffer containing 20 mM Tris pH 8, 250 mM NaCl, 20% sucrose 
and 1 mg/ml lysosyme and incubated 15 min in cold room on a rocking platform. The 
resulting sphaeroplasts were pelleted at 3700 rpm for 15 min. Pellets were kept at -80 °C for 
at 1 h and then resuspended in 700 µl of lysis buffer containing 10 mM Tris pH 8, 0.5% 
Brij58, 1/1000 dilution of benzonase, 5 mM -mercaptoethanol and protease inhibitor 
cocktail. Protein purifications were performed using using a TECAN robot: proteins were 
incubated with 300 l of NiNTA agarose resin (Qiagen) for 30 min at 4 °C for batch binding 
and washed with 10 volumes of washing buffer (300 mM NaCl, 50 mM Na2HPO4/NaH2PO4 
pH 7.5, 10 mM imidazole, 5 mM - mercaptoethanol). Proteins were eluted into 70 l of 
elution buffer (300 mM NaCl, 50 mM Na2HPO4/NaH2PO4 pH 7.5, 300 mM imidazole, 5 mM - 
mercaptoethanol). The expression level was analysed by SDS-PAGE and western blot 
analysis. The BAP tag of the three best clones was removed by BspEI digestion and 
relegation with Rapid DNA ligation kit (Roche).  
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4.2. Protein expression and purification 
4.2.1. Expression and purification of the STAT3 homodimer 
The STAT3 expression vector is a pET32a vector (Novagen) which contains the STAT3 
gene truncated at the N-Terminus, covering amino acids 127-722 (provided by C. Müller, 
EMBL, Heidelberg) who published the expression protocol and crystal structure of the 
STAT3dimer in 1998 (Becker et al., 1998a, 1998b).  
 
 
Figure 4.2: Vector map STAT3 expression vector. Strong expression of the STAT3 beta gene is 
via a T7 promoter. 
TKB1 cells were chemically transformed with the STAT3 plasmid (Stratagene). These 
engineered E. coli cells express the Elk receptor kinase domain which is required for the 
SH2 domain phosphorylation and dimerisation of STAT3 (Letwin et al., 1988). Cells were 
grown in 1 l bottles containing LB medium supplemented with 50 g/ml ampicillin and 12.5 
g/ml tetracycline at 37 °C. At OD (600 nm) 0.4 the temperature was switched to 21 °C and at 
OD 600 0.6 expression of STAT3 was induced with 1 mM IPTG (Thermo Scientific) 
overnight. The next day medium was changed to kinasing medium (M9 medium 
supplemented with 1 mM MgSO4, 11mM glucose, 0.1% casamino acids, 1.5 mM thiamine-
HCl, 53 mM 3-indoleacrylic acid, supplemented with 50 mg/ml ampicillin and 12.5 mg /ml 
tetracycline) and cells were grown for additional 2.5 h at 37 °C. Cells were harvested via 
centrifugation at 7000 rpm for 20 min and pellets resuspended in extraction buffer (20 mM 
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HEPES-HCl, pH 7.6, 0.1 M KCl, 10% glycerol, 1 mM EDTA, 10mM MnCl2, 20 mM DTT, 
protease inhibitor cocktail). Cells were lysed using a microfluidiser (M11O-L; Microfluidics 
Corporation, USA) and the lysate was cleared by centrifugation at 27000 g for 45 min at 4 °C. 
Nucleic acids and associated proteins were removed by addition of 0.1% polyethyleneimine 
final concentration to the ice cooled, stirred supernatant, incubated for 15 min and 
centrifuged at 27000 g for 20 min. STAT3 was precipitated with ammonium sulfate at 35% 
saturation and the protein pellet was dissolved in Buffer D (20 mM HEPES-HCl, pH 7.0, 200 
mM NaCl, 10 mM MgCl2, 5 mM DTT, protease inhibitor) and dialysed over night against 
Buffer D in order to remove remaining ammonium sulfate. After dialysis STAT3 was further 
purified by size exclusion chromatography (Pharmacia Superose 12 HR 10/30 column, GE 
Healthcare). The purity was evaluated by SDS-PAGE electrophoresis followed by 
Coomassie blue staining. Fractions with highest purity were pooled and stored at -80 °C. 
 
4.2.2. Expression and purification of EBNA2 fragments 
The EBNA2 expression clones F3, A11 and D9 were generated by ESRIT technology and 
have a pESPRIT002 backbone vector. 
 
   
Figure 4.3: Vector map pESPRIT002 EBNA2 F3. Expression vector for EBNA2 fragment F3 with the 
biotin acceptor peptide (BAP) included. 
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Figure 4.4: Vector map pESPRIT002 EBNA2 A11. Expression vector for EBNA2 fragment A11 with 
the biotin acceptor peptide (BAP) included. 
 
 
Figure 4.5: Vector map pESPRIT002 EBNA2 D9. Expression vector for EBNA2 fragment D9 with the 
biotin acceptor peptide (BAP) included. 
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BL-21 AI (DE3) RIL cells (Invitrogen) were transformed with the EBNA2 expression plasmids. 
Cells were grown in 1 l bottles containing LB medium supplemented with 50 g/ml 
kanamycin and 50 g/ml chloramphenicol at 37 °C. At OD (600 nm) 0.6 the temperature was 
switched to 25 °C and protein expression was induced with 0.2% L-arabinose for 16 h. Cells 
were harvested by centrifugation at 7000 rpm for 20 min and the pellet was resuspended in 
lysis buffer (25 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 5 mM - 
mercaptoethanol, protease inhibitor cocktail (Roche), 1 % Tween and Benzonase). Cells 
were lysed by sonication and cell debris removed by centrifugation at 27000g for 45 min The 
supernatant was incubated for 2 h with Ni2+-NTA agarose resin (Qiagen) at 4 °C and then 
loaded onto a plastic column. This was washed with 100ml of washing buffer (25 mM Tris-
HCl pH 8.0, 500 mM NaCl, 10 mM imidazole and 5 mM -mercaptoethanol) and eluted in 
elution buffer (50 mM Tris pH8.0, 300 mM KCl, 5mM -mercaptoethanol, and 250 mM 
imidazole). The purity was evaluated by SDS-PAGE and Coomassie blue staining. Fractions 
with highest purity were pooled, concentrated with Amicon Ultra concentrator (Millipore) and 
subjected to gel filtration (Superdex S75 10/300 column, GE Healthcare). Peak fractions 
were collected and pooled. Then the hexahistidine tag was removed by incubation with 
hexahistidine tagged tobacco etch virus protease (TEV) overnight at 4 °C. The cleaved his 
tag was removed by reversed affinity chromatography with Ni2+-NTA agarose resin (Qiagen). 
Cleaved EBNA2 fragment were concentrated and stored at -80 °C.  
4.2.3. Expression and purification of SMRT fragments 
 
 
Figure 4.6: Vector map pYUM6002 2 39L23. Expression vector of SMRT fragment 39L23 which was 
kindly provided by D. Desravines (Hart team , EMBL, Grenoble). 
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The 39L23 expression construct was generated previously using ESPRIT technology (D. 
Desravines and P. Mas). 
BL-21 AI (DE3) RIL cells (Invitrogen) were transformed with the 39L23 expression plasmid 
by electroporation. Cells were grown in 1 l bottles containing LB medium supplemented with 
50 g/ml kanamycin and 50 g /ml chloramphenicol at 37 °C. At OD (600 nm) 0.6 the 
temperature was shifted to 25 °C and protein expression was induced with 0.2% L-arabinose 
overnight. The next day cells were harvested by centrifugation at 7000 rpm for 20 min and 
the pellet was resuspended in lysis buffer (25 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM 
imidazole, 5 mM - mercaptoethanol, protease inhibitor cocktail (Roche), 1 % Tween and 
benzonase). Cells were lysed by sonication and cell debris removed by centrifugation at 
27000 g for 45 min. The cleared supernatant was then incubated at 80 °C for 10 min until the 
supernatant appeared milky. Aggregated proteins were removed by centrifugation at 27000 g 
for 20 min. The supernatant was incubated for 2 h with Ni2+-NTA agarose resin (Qiagen) at 4 
°C and then loaded onto a plastic column. This was washed with 100ml of washing buffer (25 
mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole and 5 mM - mercaptoethanol) and 
proteins were eluted in elution buffer (50 mM Tris pH8.0, 300 mM KCl, 5mM -
mercaptoethanol, and 250 mM imidazole). The hexahistidine tag was removed by incubation 
with hexahistidine tagged tobacco etch virus protease (TEV) overnight at 4 °C. The cleaved 
his tag was removed by reversed affinity chromatography with Ni2+-NTA agarose resin 
(Qiagen). The purity was evaluated by SDS-PAGE electrophoresis followed by Coomassie 
blue staining. Fractions with highest purity were pooled and stored at -80 °C after 
concentration to the desired concentration by Amicon Ultra concentrator (Millipore). 
 
4.2.4. Expression and purification of EBNA2-TAs-pGEX-4T 
and ZMYND11-pGEX-4T 
 
BL-21 AI (DE3) RIL cells (Invitrogen) were transformed with ZMYND-pGEX-4T and EBNA2-
TAs-pGEX-4T by electroporation. Single colony cells were grown in 1 l bottles containing LB 
medium supplemented with 50 g/ml ampicillin at 37 °C. At OD (600 nm) 0.6 the temperature 
was shifted to 25 °C and protein expression was induced with 1 mM IPTG (Thermo Scientific) 
for 16 h. Cells were harvested by centrifugation at 7000 rpm for 20 min and the pellet was 
resuspended in lysis buffer (25 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 5 mM 
- mercaptoethanol, protease inhibitor cocktail (Roche), 1 % Tween and benzonase). Cells 
were lysed by sonication and cell debris removed by centrifugation at 27000 g for 45 min. 
The supernatant was incubated with glutathione sepharose (GE Healthcare) overnight at 4 
°C and then loaded onto a plastic column. Proteins were washed with 100ml of PBS 0.05% 
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Tween and eluted in elution buffer (10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0). 
The GST tag was removed by incubation with Thrombin Cleave Clean kit (Sigma) according 
to the manufacturer’s protocol. The cleaved GST tag was removed by reversed affinity 
chromatography with glutathione sepharose beads. The purity was evaluated by SDS-PAGE 
and Coomassie blue staining. Fractions with highest purity were pooled and stored at -80 °C 
after concentration to the desired concentration by Amicon Ultra concentrator (Millipore). 
4.3. Kinetic binding analysis 
4.3.1. Surface plasmon resonance (SPR) 
SPR measurements were performed on a Biacore 3000 instrument (Biacore AB, Uppsala, 
Sweden) using four flow cells. The flow cell temperature was 25 °C in all experiments. 
EBNA2 and SMRT fragments were immobilised on CM5 sensorchips by conventional amine 
reactive chemistry. The surface of the carboxy-methylated dextran CM5 chip (Biacore AB, 
Uppsala, Sweden) was activated with 70 μl of a 1:1 mixture of 200 mM EDC (N-ethyl-N'-(3-
diethylaminopropyl) and 50 mM NHS (N-hydroxysuccinimide). After surface activation the 
ligand which was diluted in 10 mM sodium acetate buffer pH 6.5 was injected until an 
immobilisation level of about 2000-2500 RU (response units) was reached. Free active 
esters were blocked by injection of 70 l of 1M ethanolamine/hydrochloride at pH 8.5. 
Immobilisation flow rate was 10l/ min The analyte STAT3 was diluted in Buffer B, pH 6.5 
(20 mM HEPES-HCl, pH 7.0, 200 mM NaCl, 10 mM MgCl2, 5 mM DTT, 0.05% Tween-P20) 
and injected at various concentration according to the affinity of the binding. The 
concentration ranged from 500 pM for high affinity binding to 10 M for fragments that did not 
bind. The flow rate of binding experiments was 30 l/min After each injection bound proteins 
were removed by injection of 30 l of 1M MgCl2. Binding curves were analyzed using both 
BIAevaluation software (Biacore AB, Uppsala, Sweden) and manually using saturation 
binding values. The simple 1:1 Langmuir model and the more complex two-state model were 
both used to fit the binding data. The two-state model assumes that analyte (A) and ligand 
(L) form a first complex (AL) which is followed by a conformational change and the formation 
of a second more stable complex (AL*). From the two association and dissociation rate 
constants an apparent affinity constant can be derived. The 1:1 Langmuir model is based on 
the assumption of a simple 1:1 binding event without conformational change or multiple 
binding sites. It can be used to obtained dissociation and association rate constants as well 
as the equilibrium dissociation constant. 
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1:1 Langmuir model 
Constant Description Unit 
ka Association rate for formation of          M
-1s-1 
kd Dissociation rate for          s
-1 
KD 
   
  
  
 
M 
 
Two-state model 
Constant Description Unit 
ka1 Association rate for formation of          M
-1s-1 
ka2 Association rate for formation of          s
-1 
kd1 Dissociation rate for          s
-1 
kd2 Dissociation rate for         s
-1 
KD 
   
        
            
 
M 
 
4.3.2. Microscale thermophoresis (MST) 
For the MST experiment 100 l of STAT3 at 20 M were fluorescently labelled with a Red 
fluorescent dye (NT-647) using Monolith NT™ Protein Labeling Kit RED (NanoTemper). 
EBNA2 fragments were diluted in Buffer B , pH 6.5 (20 mM HEPES-HCl, pH 7.0, 200 mM 
NaCl, 10 mM MgCl2, 5 mM DTT, 0.05% Tween-P20) and 16 dilutions (1:1) were pipetted. 
The concentration ranged from 2 M to 62.5 pM in 10 l volume. The concentration of 
STAT3 was set constantly to 20 nM in all experiment. The proteins mixture was centrifuged 
at 27000 g for 15 min and soaked into standard capillaries (NanoTemper). Mobility chances 
were measured using the Monolith NT.115 instrument (NanoTemper) and binding generated. 
The binding affinity was calculated using the NanoTemper evaluation software.  
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4.3.3. Nuclear magnetic resonance (NMR) sample 
preparation 
 
EBNA2 fragment D9 and SMRT fragments were isotopically labelled by expression in M9 
minimal medium supplemented with ammonium 15N chloride. The adaption to minimal 
medium required two steps by transfer of the 10 ml LB starting culture first in 40 ml minimal 
medium and then in 1 l. After purification proteins were dialysed in 50 mM potassium 
phosphate buffer with 150 mM of KCl, pH 6.5. Before starting the measurement samples 
were supplemented with 10% D20 (v/v). All NMR spectra were recorded by R. Schneider 
(Blackledge NMR group, IBS, Grenoble). All experiments were recorded at 25°C using 600 
MHz or 800 MHz Varian spectrometers and analyzed using NMRPipe and Sparky software. 
The concentration of labelled proteins was 250 µM alone or decreased to nearly 50 µM when 
in complex with STAT3. Spectra of EBNA2 D9 in complex with STAT3 were recorded at a 
1:1 ratio and spectra of the complex between SMRT 39L23 and STAT3 at 1:5, 1:3, 1:1, 3:1 
and 5:1 ratios. 
 
4.4. Streptavidin agarose pull-down experiments 
EBNA2 fragments F3, A11 and D9 with BAP were expressed in LB medium supplemented 
with 50 M biotin (Sigma). Magnetic streptavidin beads (Dynabeads, Invitrogen) were 
washed three times with PBS-Tween (0.5%), then blocked in 5% fetal calf serum (FCS, 
Sigma) for 1 h. The FCS solution was aspirated and beads were incubated with EBNA2 
fragment lysate for 1 h. Beads were washed three times with PBS-Tween (0.5%), then 
STAT3 lysate was added and incubated for 30 min Beads were again washed three times for 
10 min. All incubations were performed at 4 °C with agitation. Proteins were eluted by 
addition of Laemmli buffer at 95 °C for 5 min. Eluted proteins were loaded on a 12% SDS-
PAGE (running time 1 h, 180 V) and then transferred to a nitrocellulose membrane by semi-
dry western blot transfer (Biorad) (20 V, 30 min). Proteins were detected using a rabbit 
STAT3 polyclonal antibody (Cell Signaling) and an anti-rabbit antibody-ALEXA488, and 
Streptavidin-ALEXA633. Immunofluorescence signals were detected using a Typhoon 
scanner (GE Healthcare). 
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4.5. Generation of interaction mutants 
4.5.1. Generation of GST tagged EBNA2-CR8 fragments 
The different EBNA2 fragments were amplified from EBNA2-D9-pESPRIT002 by polymerase 
chain reaction (PCR). 
Primer 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-FL forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-FL reverse) 
ATGCATGAATTCCCACCGGAAAGCCATAATTCACCGGAAGCA        (D9TA-1 forward) 
ATGCATGAGCTCTAGATCCCAGCTTTCATCCAGATCTGCCGG        (D9TA-1 reverse) 
ATGCATGAATTCCCACATAATTCACCGGAAGCACCGATTCTG        (D9TA-2 forward) 
ATGCATGAGCTCTAGCAGAATCGGTGCTTCCGGTGAATTATG        (D9TA-2 reverse) 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-3 forward) 
ATGCATGAGCTCTAGATCCCAGCTTTCATCCAGATCTGCCGG        (D9TA-3 reverse) 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-4 forward) 
ATGCATGAGCTCTAGCAGAATCGGTGCTTCCGGTGAATTATG        (D9TA-4 reverse) 
ATGCATGAATTCCCACCGGAAAGCCATAATTCACCGGAAGCA        (D9TA-5 forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-5 reverse) 
ATGCATGAATTCCCACATAATTCACCGGAAGCACCGATTCTG        (D9TA-6 forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-6 reverse) 
Template vector (50 ng) were supplemented with 500 M dNTPs, 1x Pfu reaction buffer, 200 
nM forward and reverse primer and 2.5 U Pfu polymerase (Stratagene). The volume was 
adjusted to 25 l with water. The reaction was performed in a ThermoCycler (Eppendorf) 
according to the following cycling parameters: 
 Temperature (°C) Time (sec) Cycles 
Denaturation 95 60 1 
Denaturation 95 30 
 
30 
Annealing 55 30 
Elongation 72 60 
Final elongation 72 300 1 
 
The fragments were purified using a NucleoSpin DNA Extraction Kit (Macherey Nagel). 
Amplified PCR products and receiving vector pGEX-4T were digested with EcoRI and SacI in 
buffer 1 (NEB) for 1 h. The digested vector was purified from an ethidium bromide-containing 
1% w/v agarose gel using a NucleoSpin Extraction kit and dephosphorylated by shrimp 
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alkaline phosphatase (SAP, Roche) for 30 min at 37 °C. Vector and insert were ligated using 
the Rapid ligation kit (Roche) and transformed into NEB-10 E. coli cells (NEB). Positive 
clones were verified by DNA sequencing (Macrogen).  
4.5.2. Site directed mutagenesis 
The different EBNA2 fragments were amplified from EBNA2-D9-pESPRIT002 by polymerase 
chain reaction (PCR). 
Primer 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-FL forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-FL reverse) 
ATGCATGAATTCCCACCGGAAAGCCATAATTCACCGGAAGCA        (D9TA-1 forward) 
ATGCATGAGCTCTAGATCCCAGCTTTCATCCAGATCTGCCGG        (D9TA-1 reverse) 
ATGCATGAATTCCCACATAATTCACCGGAAGCACCGATTCTG        (D9TA-2 forward) 
ATGCATGAGCTCTAGCAGAATCGGTGCTTCCGGTGAATTATG        (D9TA-2 reverse) 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-3 forward) 
ATGCATGAGCTCTAGATCCCAGCTTTCATCCAGATCTGCCGG        (D9TA-3 reverse) 
ATGCATGAATTCCCAATTCATGAACCGGAAAGCCATAATTCA        (D9TA-4 forward) 
ATGCATGAGCTCTAGCAGAATCGGTGCTTCCGGTGAATTATG        (D9TA-4 reverse) 
ATGCATGAATTCCCACCGGAAAGCCATAATTCACCGGAAGCA        (D9TA-5 forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-5 reverse) 
ATGCATGAATTCCCACATAATTCACCGGAAGCACCGATTCTG        (D9TA-6 forward) 
ATGCATGAGCTCTAGAAAGATATAATCCCAGCTTTCATCCAGATCTGC  (D9TA-6 reverse) 
 
Template vector (50 ng) were supplemented with 500M dNTPs, 1x Pfu reaction buffer, 200 
nM forward and reverse primer and 2.5 U Pfu polymerase (Stratagene). The volume was 
adjusted to 25 l with water. The reaction was performed in a ThermoCycler (Eppendorf) 
according to the following cycling parameters: 
 Temperature (°C) Time (sec) Cycles 
Denaturation 95 60 1 
Denaturation 95 30 
 
30 
Annealing 55 30 
Elongation 72 60 
Final elongation 72 300 1 
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The fragments were purified using a NucleoSpin DNA Extraction Kit (Macherey Nagel). 
Amplified PCR products and receiving vector pGEX-4T were digested with EcoRI and SacI in 
buffer 1 (NEB) for 1 h. The digested vector was purified from a ethidium bromide-containing 
1% w/v agarose gel using a NucleoSpin Extraction kit and dephosphorylated by shrimp 
alkaline phosphatase (SAP, Roche) for 30 min at 37 °C. Vector and insert were ligated using 
the Rapid ligation kit (Roche) and transformed into NEB-10 E. coli cells (NEB). Positive 
clones were verified by DNA sequencing (Macrogen).  
4.5.3. Overlap extension PCR 
EBNA2 point and deletion mutations in the mammalian expression vectors pAG155 and 
KG172 were generated by overlapping extension PCR. Therefore two fragments were 
amplified which are overlapping for a sufficient amount of base pairs.  
Primers pAG155 
GAGCCATCACCTCTTGATAGGGATCCGCTAGGATATGAC              (BamHI forward) 
GAGCGAGGAAGCGGAAGAGTCTAGAGTCGACCAGAC                  (XbaI reverse) 
GATGATTGGTATCCTCCAGCTATAGACCCCGCAGACTTAGAC           (S448A forward) 
GTCTAAGTCTGCGGGGTCTATAGCTGGAGGATACCAATCATC           (S448A reverse) 
CCCGCAGACTTAGACGAAAGTGCGGCTTACATTTTTGAGACAACAG (W458A,D459A forward)                                                                        
CTGTTGTCTCAAAAATGTAAGCCGCACTTTCGTCTAAGTCTGCGGG (W458A,D459A reverse) 
CCCGCAGACTTAGACGAAAGTGCGGCTGCCATTTTTGAGACAACAG(W458A,D459A,Y460Afor)                                                     
CTGTTGTCTCAAAAATGGCAGCCGCACTTTCGTCTAAGTCTGCGGG(W458A,D459A,Y460Arev)                         
AGCCTCTGGGCTATTATGGGACTCCGGTTCATGGTCTAAGTCTGCGGGGTC       (CR8 for) 
CATAATAGCCCAGAGGCTGACCCCGCAGACTTAGACGAAAGTTGGGATTACATTTTTGAG(CR8re) 
 
Primers KG172 
CTTGATAGGGATCCGCTAGGATATGACGTCGGGCAT                 (BamHI forward) 
CAGCGGACCCACCGGCGGCCGCCCGGCTGCC                       (NotI reverse) 
CCTCCAGCTATAGACCCCGCAGACTTAGACGAAAGTTGG              (S448A forward) 
CCAACTTTCGTCTAAGTCTGCGGGGTCTATAGCTGGAGG              (S448A reverse)  
AATAGCCCAGAGGCTGACCCCGCAGACTTAGACGAAAGTTGGGATTACATTTTTGAG (CR8 for)                     
TAAGTCTGCGGGGTCAGCCTCTGGGCTATTATGGGACTCCGGTTCATGTATTG     (CR8 rev)  
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Template vector at 100 ng (pAG155 or KG172 EBNA2 vector), 500 M dNTPs, 1x Pfu 
reaction buffer, 200 nM forward and reverse primer and 2.5U Pfu polymerase (Stratagene) 
were adjusted with water to 25 l. The first reaction used the parameters: 
 
 Temperature (°C) Time (sec) Cycles 
Denaturation 95 60 1 
Denaturation 95 30 
 
 
30 
Annealing 55 30 
Elongation 72 120 
Final elongation 72 300 1 
 
The amplified fragments were gel purified from a 1% ethidium bromide agarose gel using a 
NucleoSpin Extraction kit (Macherey Nagel) and both fragments were mixed in equal molar 
ratio supplemented with 500M dNTPs, 1x Pfu reaction buffer and 2.5U Pfu polymerase. A 
second reaction cycle followed in order to generate one longer fragment out of the two 
shorter fragments. The second reaction followed these parameters: 
 Temperature (°C) Time (sec) Cycles 
Denaturation 95 60 1 
Denaturation 95 30 
 
20 
Annealing 55 30 
Elongation 72 120 
Final elongation 72 300 1 
 
Both, fragments and pAG155 EBNA2 vector were digested with BamHI and XbaI/NotI in 
buffer 4 (XbaI) or 3 (NotI) supplemented with BSA for 2 h at 37 °C. Inserts and vector were 
gel purified from a 1% ethidium bromide agarose gel using a NucleoSpin Extraction kit 
(Macherey Nagel) and the vector was dephosphorylated by shrimp alkaline phosphatase 
(SAP, Roche) for 30 min at 37 °C. Vector and insert were ligated using the Rapid ligation kit 
(Roche) and transformed into Mach1 E.coli cells (Invitrogen). Positive clones were verified by 
DNA sequencing (Macrogen). 
 
 
 
97 
 
4.5.4. Generation of SMRT fragment mammalian expression 
vectors 
 
The different SMRT fragments were amplified from SMRT iso 1 (1-1195) and SMRT iso 2 
(1012-2075) by polymerase chain reaction (PCR). Fragments were inserted into pcDNA3-
myc. 
 
Primer  
ATGCATGAATTCAAGAAGAAGCGTAAGGTAATGTCGGGATCCACACAGCCTG (SMRT1 forward)           
ATGCATGGATCCTCAGACCTGGCGGTCTTTGTACACCTTC             (SMRT1 reverse) 
ATGCATGAATTCAAGAAGAAGCGTAAGGTAATGAACATGTGGAGTGAGCAGGAGAAG(SMRT2 for)                                     
ATGCATGGATCCTCAGGGAAGGCCGAGGAGCCC                        (SMRT2 rev) 
ATGCATGAATTCAAGAAGAAGCGTAAGGTAGTCAAGAGCGAGTGCACGGAGG (SMRT3 forward)           
ATGCATGGATCCTCATTCTTGCCTTCGTAGATGACGTGG              (SMRT3 reverse) 
ATGCATGAATTCAAGAAGAAGCGTAAGGTAGGGCCACGTCTTGTCCTATGAGG(SMRT4 forward)     
ATGCATGGATCCTCATGATGTAGTCATTGATGATGGTCTGCC           (SMRT4 reverse) 
ATGCATGAATTCAAGAAGAAGCGTAAGGTACCTCGCAGCAGATGCACCACA  (SMRT5 forward)                   
ATGCATGGATCCTCACCGCAGGTGTGGGAGGTGG                   (SMRT5 reverse) 
ATGCATGAATTCAAGAAGAAGCGTAAGGTACCGCTGCCTGAGAGCCAGC    (SMRT6 forward)                
ATGCATGGATCCTCATCACTCGCTGTCGGAGAGTGTCTC              (SMRT6 reverse) 
 
Fifty nanograms of template vector were supplemented with 500 M dNTPs, 1x Pfu reaction 
buffer, 200 nM forward and reverse primer and 2.5 U Pfu polymerase (Stratagene). The 
volume was adjusted to 25 l with water. The reaction was performed in a ThermoCylcer 
(Eppendorf) according to the following cycling parameters: 
 Temperature (°C) Time (sec) Cycles 
Denaturation 95 60 1 
Denaturation 95 30 
 
 
30 
Annealing 50 60 
Elongation 72 120 
Final elongation 72 300 1 
 
The fragments were purified using a NucleoSpin DNA Extraction Kit (Macherey Nagel). 
Amplified PCR products and receiving vector pcDNA3-myc were digested with EcoRI and 
BamHI in buffer 3 (NEB) for 1 h. The digested vector was purified from an ethidium bromide-
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containing 1% w/v agarose gel using a NucleoSpin Extraction kit and dephosphorylated by 
shrimp alkaline phosphatase (SAP, Roche) for 30 min at 37 °C. Vector and insert were 
ligated using the Rapid ligation kit (Roche) and transformed into NEB-10 E.coli cells (NEB). 
Positive clones were verified by DNA sequencing (Macrogen).  
 
4.6. Electrophoretic mobility shift assay (EMSA) 
An electromobility shift assay (EMSA) was performed using ALEXA488 fluorescently labelled 
STAT3 binding oligos (GAATCCTAAGTGCATTTCCCGTAAATCTTGAAGTCGCG). 1 M of 
STAT3 binding oligo was incubated with the STAT3 homodimer (20M) alone or together 
with wild-type or CR8 D9 EBNA2 proteins in different ratios (1:2, 1:1 and 2:1) for 30 min in 
the dark. Sample buffer was buffer B, pH 6.5 (20 mM HEPES-HCl, pH 7.0, 200 mM NaCl, 10 
mM MgCl2, 5 mM DTT, 0.05% Tween-P20). Afterwards oligo alone and protein-oligo 
complexes were electrophoresed on a 6% native polyacrylamide gel at 4 °C for 2 h. The 
membrane was analysed using a Typhoon scanner (GE Healthcare). 
4.7. Limited proteolysis 
STAT3 (20 g), EBNA2-D9 (60 g) and the complex of both were digested for 5, 15, 30 and 
60 min at room temperature with 20 ng of protease (trypsin, elastase and chymotrypsin). The 
digest was terminated by adding Laemmli buffer to the samples and boiling at 95 °C or 
freezing and storage at -20 °C. Aliquots were electrophoresed on 12% SDS-PAGE and 
Coomassie stained. For N-terminal sequencing the fragments of interest were transferred 
onto a PVDF membrane and then submitted to the N-terminal sequencing facility at the IBS, 
Grenoble (J.-P. Andrieu). For mass spectrometry analysis, frozen aliquots containing all 
protein fragments plus peptidase were submitted to the mass spectrometry facility at the IBS, 
Grenoble (L. Signor). 
4.8. Crystallisation trials 
Purified STAT3 was concentrated to 5 mg/ml with an Amicon Ultra concentrator (Millipore) 
and CR8 synthetic peptide was added in 3 time molar ratio. The protein complex was then 
submitted to the high-throughput nanodrop crystallisation facility at EMBL, Grenoble.  Over 
70 crystallisation conditions resulted in positive hits. 12 crystals have been tested and 4 
complete datasets have been collected at Proxima I (SOLEIL, Paris). Best resolution 
obtained was 6.5 Å (Space Group I41, a= b=174.0, c=79.4).  
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Sreening kits used by the HTX lab: 
 
Screen contents Supplier 
The Classics Qiagen/Nextal 
Crystal Screen Lite & PEG/Ion Hampton Research 
MembFac & Natrix Hampton Research 
QuickScreen & Grid screens 
Ammonium Sulfate, Sodium 
Malonate - Sodium Formate 
Hampton Research - Home 
made 
Grid screens PEG 6K, PEG/LiCl, 
MPD - Screen Mme 
Hampton Research - Home 
made 
Index Screen Hampton Research 
 
4.9. Cell based assays 
HEK293 cells (ATCC-CLR 1573) were maintained in DMEM medium supplemented with 
10% fetal bovine serum (FCS). Cells were harvested twice a week by trypsination and were 
split 1:10. DG75 cells (ATCC-CLR 2625) were maintained in RPMI medium supplemented 
with 10% FCS, 2% L-glutamine and 1% pen-strep. Cells were split 1:1 twice a week.  
4.9.1. Generation of stable, monoclonal cells expressing 
the firefly luciferase gene under control of a STAT3 
promoter 
 
HEK293 cells were transduced using lentiviral particles (Cignal Lenti STAT3 Reporter (luc) 
Kit: CLS-6028L) containing the firefly luciferase gene under control of a STAT3 promoter 
region. 2x105 cells were transduced with one vial of lentiviral particles (MOI=10). The next 
day the virus was removed and cells were washed twice. Five days after transduction 500 
ng/ml of puromycin were added to the growth medium for selection. Two weeks after 
selection, cells were pipetted in 96 well plates in a limiting dilution series in order to generate 
monoclonal cells. Stably transfected HEK293-STAT3-Luc cells were co-transfected with 
increasing concentration of KG172 EBNA2 expression plasmid (12.5-100 ng), constant 
concentration of mutants (S448A and CR8 at 100 ng) or SMRT fragment expression 
vector. Twenty-four h later cells were treated with 100 ng/ml of LIF for 6 h. Luciferase signals 
were detected using a Wallac luminometer.  
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4.9.2. CBF1 reporter assay 
CBF1-luciferase reporter plasmid (5 g), -galactosidase normalisation vector (3 g) and 1 
g of target vector (pAG155 empty vector, pAG155 EBNA2 wild-type or point mutant 
expression vector) were transfected into 5x106 DG75 cells by electroporation at 0.22 kV and 
950 F. Experiments were performed in triplicates. After transfection cells were grown in 5 ml 
growth medium for 2 days. Then cells were harvested by centrifugation at 300 g for 10 min 
and washed with 1 ml of PBS. Pellets were lysed in 100 l ice cool extraction buffer (50% 
(w/v) glycerine, 5% (w/v) Triton x-100, 10 mM EDTA, 125 mM Tris-HCl pH7.8 and 2 mM 
DTT) and the supernatant was cleared in a microcentrifuge at 15300 rpm for 15 min. 
Supernatant was stored at -80 °C before being assayed. Ten l of cell lysate were pipetted 
into white 96 well plates in duplicate for each assay. For the-galactosidase assay 100 l of 
assay buffer (100 mM Na-P pH 8.0, 1% Galacton Plus, 0.1 mM MgCl2) were added to each 
well and incubated for 15  min. Luciferase and -galactosidase assays were performed in an 
automated luminometer that injects 50 l of either luciferase assay buffer (20 mM Tricin, 1.07 
mM MgCO3, 2.67 MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 M acetyl-CoA, 470 M 
Luciferin and 530 M ATP) or -galactosidase enhancer buffer (0.2 M NaOH and 9% 
Emerald enhancer) to each well shortly before measuring the luciferase or -galactosidase 
signal. 
4.9.3. STAT3 reporter assay 
HEK293 were harvested with Trypsin/EDTA (0.05%) (Invitrogen) and 2.5x105 cells were 
seeded into each well of a 6 well plate. The next day 1 g of STAT3 firefly luciferase reporter 
and constitutively active renilla luciferase plasmid mixtures (40:1, SABioscience) were co-
transfected with increasing concentration of pAG155 EBNA2 expression plasmid (100 ng, 
200 ng, 300 ng and 400 ng) or constant concentration of pAG155 EBNA2 point mutants via 
lipofectamine (Invitrogen) transfection protocol. Twenty  h later, cells were stimulated with 
100 ng/ml of leukemia inhibitory factor (LIF) for 6  h. Cells were harvested by scraping and 
centrifugation at 300 g for 10  min Then cells were washed with 1 ml of PBS and pellets were 
lysed in 100 l ice cool 1x extraction buffer (dual luciferase reporter assay kit, Promega) and 
the supernatant cleared by microcentrifugation at 15300 rpm for 15  min The firefly and 
renilla luciferase signal were detected using commercially available assay reagents (dual 
luciferase reporter assay kit, Promega) according to the manufacturer’s protocol and signals 
were recorded with a luminometer.   
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Appendix 
 
 
 
 
Figure A.1: pESPRIT002-EBNA2 double truncated DNA smear. Fractions of 3.5kb to 3kb, 3kb to 
2.5kb and 2.5kb to 2 kb were isolated from a 0.5% w/v agarose gel. 
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Figure A.2: Colony blot of EBNA2 expression library clones. 27648 clones were printed on a 
nitrocellulose membrane and signals for the 6xHis tag (red signal) and BAP(green signal) were 
detected with Streptavidin- Alexa488 and His tag primary antibody together with secondary antibody 
anti-mouse Alexa532  
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Figure A.3: Western blot of the 96 best expressing EBNA2 expression clones. NiNTA-purified 
proteins were detected via the BAP using Streptavidin- Alexa488. 
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Figure A.4: HSQC sprectrum of EBNA2-D9 in complex with STAT3. D9 alone (black) and D9-
STAT3 complex (green). The ration between D9 and STAT3 was 1:1. Spectra recorded by 
R.Schneider (Blackledge lab, IBS Grenoble). 
 
 
116 
 
 
Figure A.5: HSQC sprectrum of SMRT-39L23 in complex with STAT3. Orange peaks indicate free 
39L23 and blue peaks indicate 39L23 in complex with STAT3. The protein ratio was 1:1. Spectra 
recorded by R.Schneider (Blackledge lab, IBS Grenoble). 
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Figure A.6: HSQC sprectrum of SMRT-27M12 in complex with STAT3. . Orange peaks indicate 
free 27M12 and blue peaks indicate 27M12 in complex with STAT3. The protein ratio was 1:1. Spectra 
recorded by R.Schneider (Blackledge lab, IBS Grenoble). 
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Figure A.7: HSQC sprectrum of the assigned SMRT-39L23 fragment. Orange peaks indicate free  
39L23, green peaks indicate 39L23 in complex with 5x access of STAT3. 
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Figure A.8: Peak intensity changed of the amino acids in 39L23 effected by STAT3 binding. 
Each lane corresponds to one residue of fragment 39L23 starting from 1-199. Changes occur upon 
STAT3 titration from 1- to 5-fold access. Assignment performed by R. Schneider (Blackledge lab, IBS 
Grenoble). 
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EBNA2 synthetic gene sequence: 
 
   1 ATGCCGACCT TTTATCTGGC ACTGCATGGT GGTCAGACCT ATCATCTGAT  
  51 TGTTGATACC GATAGCCTGG GTAATCCGAG CCTGAGCGTT ATTCCGAGCA  
 101 ATCCGTATCA AGAACAGCTG AGCGATACAC CGCTGATTCC GCTGACCATT  
 151 TTTGTTGGTG AAAATACCGG TGTTCCGCCT CCGCTGCCTC CTCCTCCACC  
 201 ACCTCCGCCT CCGCCACCGC CTCCCCCACC TCCACCACCG CCCCCACCCC  
 251 CACCTCCCCC TCCGAGTCCG CCTCCACCGC CACCCCCTCC ACCGCCGCCT  
 301 CAACGTCGTG ATGCCTGGAC CCAAGAACCG AGTCCGCTGG ATCGTGATCC  
 351 GCTGGGTTAT GATGTTGGTC ATGGTCCGCT GGCAAGCGCA ATGCGTATGC  
 401 TGTGGATGGC AAACTATATT GTTCGTCAGA GCCGTGGTGA TCGTGGTCTG  
 451 ATTCTGCCGC AGGGTCCGCA GACCGCACCG CAAGCACGTC TGGTTCAGCC  
 501 GCATGTTCCG CCTCTGAGAC CGACCGCACC GACCATTCTG AGTCCGCTGA  
 551 GCCAGCCTAG ACTGACACCG CCTCAGCCGC TGATGATGCC TCCGCGTCCG  
 601 ACACCTCCGA CTCCTCTGCC TCCGGCAACC CTGACCGTTC CGCCTCGTCC  
 651 GACCCGTCCG ACAACCTTAC CGCCTACACC GCTGCTGACC GTTCTGCAGC  
 701 GTCCGACAGA ACTGCAGCCG ACCCCGAGCC CTCCGCGTAT GCACTTACCG  
 751 GTTCTGCATG TGCCGGATCA GAGCATGCAC CCGCTGACCC ATCAGAGCAC  
 801 CCCGAATGAT CCTGATTCAC CGGAACCGCG TAGCCCGACC GTGTTTTATA  
 851 ACATTCCGCC TATGCCGCTG CCTCCGAGCC AGTTACCGCC TCCTGCAGCA  
 901 CCGGCACAGC CTCCGCCTGG TGTTATTAAT GATCAGCAGC TGCATCATCT  
 951 GCCGAGCGGT CCGCCTTGGT GGCCTCCGAT TTGTGATCCT CCGCAGCCGA  
1001 GCAAAACCCA GGGTCAGAGT CGTGGTCAGT CACGTGGTCG TGGTCGCGGT  
1051 CGTGGTAGAG GTCGCGGTAA AGGTAAAAGC CGTGATAAAC AGCGTAAACC  
1101 GGGTGGTCCG TGGCGTCCTG AACCGAATAC CAGCAGCCCG AGCATGCCGG  
1151 AACTGAGTCC GGTTCTGGGT CTGCATCAGG GTCAGGGTGC CGGTGATAGC  
1201 CCGACACCGG GTCCGAGCAA TGCAGCACCG GTTTGTCGTA ATAGCCATAC  
1251 CGCAACCCCG AATGTTAGCC CGATTCATGA ACCGGAAAGC CATAATTCAC  
1301 CGGAAGCACC GATTCTGTTT CCAGATGATT GGTATCCGCC TAGCATTGAT  
1351 CCGGCAGATC TGGATGAAAG CTGGGATTAT ATCTTTGAAA CCACCGAAAG  
1401 CCCGAGCAGT GATGAAGATT ATGTTGAAGG TCCGAGCAAA CGTCCGCGTC  
1451 CGAGCATTCA GTAA  
 
 
EBNA2 amino acid sequence: 
 
1   MPTFYLALHG GQTYHLIVDT DSLGNPSLSV IPSNPYQEQL SDTPLIPLTI  
51  FVGENTGVPP PLPPPPPPPP PPPPPPPPPP PPPPPPPPSP PPPPPPPPPP  
101 QRRDAWTQEP SPLDRDPLGY DVGHGPLASA MRMLWMANYI VRQSRGDRGL  
151 ILPQGPQTAP QARLVQPHVP PLRPTAPTIL SPLSQPRLTP PQPLMMPPRP  
201 TPPTPLPPAT LTVPPRPTRP TTLPPTPLLT VLQRPTELQP TPSPPRMHLP  
251 VLHVPDQSMH PLTHQSTPND PDSPEPRSPT VFYNIPPMPL PPSQLPPPAA  
301 PAQPPPGVIN DQQLHHLPSG PPWWPPICDP PQPSKTQGQS RGQSRGRGRG  
351 RGRGRGKGKS RDKQRKPGGP WRPEPNTSSP SMPELSPVLG LHQGQGAGDS  
401 PTPGPSNAAP VCRNSHTATP NVSPIHEPES HNSPEAPILF PDDWYPPSID  
451 PADLDESWDY IFETTESPSS DEDYVEGPSK RPRPSIQ  
 
  
 
121 
 
Sequence of synthetic codon optimized DNA encoding EBNA2 C-terminal region 
(from BamH1 to XbaI restriction site) 
1    gaattccatc atgcctacat tctatcttgc gttacatggg ggacaaacat  
51   atcatctaat tgttgacacg gatagtcttg gaaacccgtc actctcagta  
101  attccctcga atccctacca ggaacaactg tcagacactc cattaattcc  
151  actaacaatc tttgttgggg aaaacacggg ggtgccccca ccactcccac  
201  cacccccccc accaccaccc ccaccacccc caccaccccc accaccccca  
251  ccacccccac cacctccacc accttcacca ccacccccgc ccccaccacc  
301  cccaccacct cagcgcaggg atgcctggac acaagagcca tcacctcttg  
351  atagggatcc gctaggatat gacgtcgggc atggacctct agcatctgct  
401  atgcgaatgc tttggatggc taattatatt gtaagacaat cacggggtga  
451  ccggggcctt attttgccac aaggcccaca aacagcccct caggccaggt  
501  tggtccagcc acatgtcccc cctctacgcc cgacagcacc caccattttg  
551  tcacctctgt cacaaccgag gcttacccct ccacaaccac tcatgatgcc  
601  accaaggcct acccctccta cccctctgcc acctgcaaca ctaacggtgc  
651  caccaaggcc tacccgtcct accactctgc cacccacacc actactcacg  
701  gtactacaaa ggcctaccga acttcaaccc acaccatcac caccacgcat  
751  gcatctccct gtcttgcatg tgccagacca atcaatgcac cctcttactc  
801  atcaaagcac cccaaatgat ccagatagtc cagaaccacg gtccccgact  
851  gtattttata acattccacc tatgccatta cccccctcac aattgccacc  
901  accagcagca ccagcacagc cacctccagg ggtcatcaac gaccaacaat  
951  tacatcatct accctcgggg ccaccatggt ggccacccat ctgcgacccc  
1001 ccgcaaccct ctaagactca aggccagagc cggggacaga gcagggggag  
1051 gggcaggggc aggggcaggg gcaggggcaa gggcaagtcc agggacaagc  
1101 aacgcaagcc cggtggacct tggagaccag agccaaacac ctccagtcct  
1151 agcatgcctg aactaagtcc agtcctcggt cttcatcagg gacaaggggc  
1201 tggggactca ccaactcctg gcccatccaa tgccgccccc gtttgtagaa  
1251 attcacacac ggcaacccct aacgtttcac caatacatga accggagtcc  
1301 cataatagcc cagaggctcc cattctcttc cccgatgatt ggtatcctcc  
1351 atctatagac cccgcagact tagacgaaag ttgggattac atttttgaga  
1401 caacagaatc tcctagctca gatgaagatt atgtggaggg acccagtaaa  
1451 agacctcgcc cctccatcca gccatacgat gttccagatt acgctagcta  
1501 aagatcttat taaagcagaa cttgtttatt gcagcttata atggttacaa  
1551 ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc  
1601 attctagttg tggtttgtcc aaactcatca atgtatctta tcatgtctgg  
1651 tcgactctag a  
 
 
 
 
Sequence of SMRT synthetic codon optimized DNA 
1    atgtcgggat ccacacagcc tgtggcacag acgtggaggg ccactgagcc  
51   ccgctacccg ccccacagcc tttcctaccc agtgcagatc gcccggacgc  
101  acacggacgt cgggctcctg gagtaccagc accactcccg cgactatgcc  
151  tcccacctgt cgcccggctc catcatccag ccccagcggc ggaggccctc  
201  cctgctgtct gagttccagc ccgggaatga acggtcccag gagctccacc  
251  tgcggccaga gtcccactca tacctgcccg agctggggaa gtcagagatg  
301  gagttcattg aaagcaagcg ccctcggcta gagctgctgc ctgaccccct  
351  gctgcgaccg tcacccctgc tggccacggg ccagcctgcg ggatctgaag  
401  acctcaccaa ggaccgtagc ctgacgggca agctggaacc ggtgtctccc  
451  cccagccccc cgcacactga ccctgagctg gagctggtgc cgccacggct  
501  gtccaaggag gagctgatcc agaacatgga ccgcgtggac cgagagatca  
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551  ccatggtaga gcagcagatc tctaagctga agaagaagca gcaacagctg  
601  gaggaggagg ctgccaagcc gcccgagcct gagaagcccg tgtcaccgcc  
651  gcccatcgag tcgaagcacc gcagcctggt gcagatcatc tacgacgaga  
701  accggaagaa ggctgaagct gcacatcgga ttctggaagg cctggggccc  
751  caggtggagc tgccgctgta caaccagccc tccgacaccc ggcagtatca  
801  tgagaacatc aaaataaacc aggcgatgcg gaagaagcta atcttgtact  
851  tcaagaggag gaatcacgct cggaaacaat gggagcagaa gttctgccag  
901  cgctatgacc agctcatgga ggcctgggag aagaaggtgg agcgcatcga  
951  gaacaacccc cggcggcggg ccaaggagag caaggtgcgc gagtactacg  
1001 agaagcagtt ccctgagatc cgcaagcagc gcgagctgca ggagcgcatg  
1051 cagagcaggg tgggccagcg gggcagtggg ctgtccatgt cggccgcccg  
1101 cagcgagcac gaggtgtcag agatcatcga tggcctctca gagcaggaga  
1151 acctggagaa gcagatgcgc cagctggccg tgatcccgcc catgctgtac  
1201 gacgctgacc agcagcgcat caagttcatc aacatgaacg ggcttatggc  
1251 cgaccccatg aaggtgtaca aagaccgcca ggtcatgaac atgtggagtg  
1301 agcaggagaa ggagaccttc cgggagaagt tcatgcagca tcccaagaac  
1351 tttggcctga tcgcatcatt cctggagagg aagacagtgg ctgagtgcgt  
1401 cctctattac tacctgacta agaagaatga gaactataag agcctggtga  
1451 gacggagcta tcggcgccgc ggcaagagcc agcagcagca acaacagcag  
1501 cagcagcagc agcagcagca gcagcagcag cccatgcccc gcagcagcca  
1551 ggaggagaaa gatgagaagg agaaggaaaa ggaggcggag aaggaggagg  
1601 agaagccgga ggtggagaac gacaaggaag acctcctcaa ggagaagaca  
1651 gacgacacct caggggagga caacgacgag aaggaggctg tggcctccaa  
1701 aggccgcaaa actgccaaca gccagggaag acgcaaaggc cgcatcaccc  
1751 gctcaatggc taatgaggcc aacagcgagg aggccatcac cccccagcag  
1801 agcgccgagc tggcctccat ggagctgaat gagagttctc gctggacaga  
1851 agaagaaatg gaaacagcca agaaaggtct cctggaacac ggccgcaact  
1901 ggtcggccat cgcccggatg gtgggctcca agactgtgtc gcagtgtaag  
1951 aacttctact tcaactacaa gaagaggcag aacctcgatg agatcttgca  
2001 gcagcacaag ctgaagatgg agaaggagag gaacgcgcgg aggaagaaga  
2051 agaaagcgcc ggcggcggcc agcgaggagg ctgcattccc gcccgtggtg  
2101 gaggatgagg agatggaggc gtcgggcgtg agcggaaatg aggaggagat  
2151 ggtggaggag gctgaagcca ctgtcaacaa cagctcagac accgagagca  
2201 tcccctctcc tcacactgag gccgccaagg acacagggca gaatgggccc  
2251 aagcccccag ccaccctggg cgccgacggg ccacccccag ggccacccac  
2301 cccaccaccg gaggacatcc cggcccccac tgagcccacc ccggcctctg  
2351 aagccaccgg agcccctacg cccccaccag cacccccatc gccctctgca  
2401 cctcctcctg tggtccccaa ggaggagaag gaggaggaga ccgcagcagc  
2451 gcccccagtg gaggaggggg aggagcagaa gccccccgcg gctgaggagc  
2501 tggcagtgga cacagggaag gccgaggagc ccgtcaagag cgagtgcacg  
2551 gaggaagccg aggaggggcc ggccaagggc aaggacgcgg aggccgctga  
2601 ggccacggcc gagggggcgc tcaaggcaga gaagaaggag ggcgggagcg  
2651 gcagggccac cacagccaag agctcgggcg ccccccagga cagcgactcc  
2701 agtgctacct gcagtgcaga cgaggtggat gaggccgagg gcggcgacaa  
2751 gaaccggctg ctgtccccaa ggcccagcct cctcaccccg actggcgacc  
2801 cccgggccaa tgcctcaccc cagaagccac tggacctgaa gcagctgaag  
2851 cagcgagcgg ctgccatccc ccccatccag gtcaccaaag tccatgagcc  
2901 cccccgggag gacgcagctc ccaccaagcc agctccccca gccccaccgc  
2951 caccgcaaaa cctgcagccg gagagcgacg cccctcagca gcctggcagc  
3001 agcccccggg gcaagagcag gagcccggca ccccccgccg acaaggaggc  
3051 agagaagcct gtgttcttcc cagccttcgc agccgaggcc cagaagctgc  
3101 ctggggaccc cccttgctgg acttccggcc tgcccttccc cgtgcccccc  
3151 cgtgaggtga tcaaggcctc cccgcatgcc ccggacccct cagccttctc  
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3201 ctacgctcca cctggtcacc cactgcccct gggcctccat gacactgccc  
3251 ggcccgtcct gccgcgccca cccaccatct ccaacccgcc tcccctcatc  
3301 tcctctgcca agcaccccag cgtcctcgag aggcaaatag gtgccatctc  
3351 ccaaggaatg tcggtccagc tccacgtccc gtactcagag catgccaagg  
3401 ccccggtggg ccctgtcacc atggggctgc ccctgcccat ggaccccaaa  
3451 aagctggcac ccttcagcgg agtgaagcag gagcagctgt ccccacgggg  
3501 ccaggctggg ccaccggaga gcctgggggt gcccacagcc caggaggcgt  
3551 ccgtgctgag agggacagct ctgggctcag ttccgggcgg aagcatcacc  
3601 aaaggcattc ccagcacacg ggtgccctcg gacagcgcca tcacataccg  
3651 cggctccatc acccacggca cgccagctga cgtcctgtac aagggcacca  
3701 tcaccaggat catcggcgag gacagcccga gtcgcttgga ccgcggccgg  
3751 gaggacagcc tgcccaaggg ccacgtcatc tacgaaggca agaagggcca  
3801 cgtcttgtcc tatgagggtg gcatgtctgt gacccagtgc tccaaggagg  
3851 acggcagaag cagctcagga cccccccatg agacggccgc ccccaagcgc  
3901 acctatgaca tgatggaggg ccgcgtgggc agagccatct cctcagccag  
3951 catcgaaggt ctcatgggcc gtgccatccc gccggagcga cacagccccc  
4001 accacctcaa agagcagcac cacatccgcg ggtccatcac acaagggatc  
4051 cctcggtcct acgtggaggc acaggaggac tacctgcgtc gggaggccaa  
4101 gctcctaaag cgggagggca cgcctccgcc cccaccgccc tcacgggacc  
4151 tgaccgaggc ctacaagacg caggccctgg gccccctgaa gctgaagccg  
4201 gcccatgagg gcctggtggc cacggtgaag gaggcgggcc gctccatcca  
4251 tgagatcccg cgcgaggagc tgcggcacac gcccgagctg cccctggccc  
4301 cgcggccgct caaggagggc tccatcacgc agggcacccc gctcaagtac  
4351 gacaccggcg cgtccaccac tggctccaaa aagcacgacg tacgctccct  
4401 catcggcagc cccggccgga cgttcccacc cgtgcacccg ctggatgtga  
4451 tggccgacgc ccgggcactg gaacgtgcct gctacgagga gagcctgaag  
4501 agccggccag ggaccgccag cagctcgggg ggctccattg cgcgcggcgc  
4551 cccggtcatt gtgcctgagc tgggtaagcc gcggcagagc cccctgacct  
4601 atgaggacca cggggcaccc tttgccggcc acctcccacg aggttcgccc  
4651 gtgaccacgc gggagcccac gccgcgcctg caggagggca gcctttcgtc  
4701 cagcaaggca tcccaggacc gaaagctgac gtcgacgcct cgtgagatcg  
4751 ccaagtcccc gcacagcacc gtgcccgagc accacccaca ccccatctcg  
4801 ccctatgagc acctgcttcg gggcgtgagt ggcgtggacc tgtatcgcag  
4851 ccacatcccc ctggccttcg accccacctc cataccccgc ggcatccctc  
4901 tggacgcagc cgctgcctac tacctgcccc gacacctggc ccccaacccc  
4951 acctacccgc acctgtaccc accctacctc atccgcggct accccgacac  
5001 ggcggcgctg gagaaccggc agaccatcat caatgactac atcacctcgc  
5051 agcagatgca ccacaacgcg gccaccgcca tggcccagcg agctgatatg  
5101 ctgaggggcc tctcgccccg cgagtcctcg ctggcactca actacgctgc  
5151 gggtccccga ggcatcatcg acctgtccca agtgccacac ctgcctgtgc  
5201 tcgtgccccc gacaccaggc accccagcca ccgccatgga ccgccttgcc  
5251 tacctcccca ccgcgcccca gcccttcagc agccgccaca gcagctcccc  
5301 actctcccca ggaggtccaa cacacttgac aaaaccaacc accacgtcct  
5351 cgtccgagcg ggagcgagac cgggatcgag agcgggaccg ggatcgggag  
5401 cgggaaaagt ccatcctcac gtccaccacg acggtggagc acgcacccat  
5451 ctggagacct ggtacagagc agagcagcgg cagcagcggc agcagcggcg  
5501 ggggtggggg cagcagcagc cgccccgcct cccactccca tgcccaccag  
5551 cactcgccca tctcccctcg gacccaggat gccctccagc agagacccag  
5601 tgtgcttcac aacacaggca tgaagggtat catcaccgct gtggagccca  
5651 gcacgcccac ggtcctgagg tccacctcca cctcctcacc cgttcgcccg  
5701 gctgccacat tcccacctgc cacccactgc ccactgggcg gcaccctcga  
5751 tggggtctac cctaccctca tggagcccgt cttgctgccc aaggaggccc  
5801 cccgggtcgc ccggccagag cggccccgag cagacaccgg ccatgccttc  
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5851 ctcgccaagc ccccagcccg ctccgggctg gagcccgcct cctcccccag  
5901 caagggctcg gagccccggc ccctagtgcc tcctgtctct ggccacgcca  
5951 ccatcgcccg cacccctgcg aagaacctcg cacctcacca cgccagcccg  
6001 gacccgccgg cgccacctgc ctcggcctcg gacccgcacc gggaaaagac  
6051 tcaaagtaaa cccttttcca tccaggaact ggaactccgt tctctgggtt  
6101 accacggcag cagctacagc cccgaagggg tggagcccgt cagccctgtg  
6151 agctcaccca gtctgaccca cgacaagggg ctccccaagc acctggaaga  
6201 gctcgacaag agccacctgg agggggagct gcggcccaag cagccaggcc  
6251 ccgtgaagct tggcggggag gccgcccacc tcccacacct gcggccgctg  
6301 cctgagagcc agccctcgtc cagcccgctg ctccagaccg ccccaggggt  
6351 caaaggtcac cagcgggtgg tcaccctggc ccagcacatc agtgaggtca  
6401 tcacacagga ctacacccgg caccacccac agcagctcag cgcacccctg  
6451 cccgcccccc tctactcctt ccctggggcc agctgccccg tcctggacct  
6501 ccgccgccca cccagtgacc tctacctccc gcccccggac catggtgccc  
6551 cggcccgtgg ctccccccac agcgaagggg gcaagaggtc tccagagcca  
6601 aacaagacgt cggtcttggg tggtggtgag gacggtattg aacctgtgtc  
6651 cccaccggag ggcatgacgg agccagggca ctcccggagt gctgtgtacc  
6701 cgctgctgta ccgggatggg gaacagacgg agcccagcag gatgggctcc  
6751 aagtctccag gcaacaccag ccagccgcca gccttcttca gcaagctgac  
6801 cgagagcaac tccgccatgg tcaagtccaa gaagcaagag atcaacaaga  
6851 agctgaacac ccacaaccgg aatgagcctg aatacaatat cagccagcct  
6901 gggacggaga tcttcaatat gcccgccatc accggaacag gccttatgac  
6951 ctatagaagc caggcggtgc aggaacatgc cagcaccaac atggggctgg  
7001 aggccataat tagaaaggca ctcatgggtg gcggcgggaa ggccaaggtc  
7051 tctggcagac ccagcagccg aaaagccaag tccccggccc cgggcctggc  
7101 atctggggac cggccaccct ctgtctcctc agtgcactcg gagggagact  
7151 gcaaccgccg gacgccgctc accaaccgcg tgtgggagga caggccctcg  
7201 tccgcaggtt ccacgccatt cccctacaac cccctgatca tgcggctgca  
7251 ggcgggtgtc atggcttccc cacccccacc gggcctcccc gcgggcagcg  
7301 ggcccctcgc tggcccccac cacgcctggg acgaggagcc caagccactg  
7351 ctctgctcgc agtacgagac actctccgac agcgagtga 
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